注射剤送達市場 – 2030年までの世界予測

本レポートは、注射剤送達市場を、製品、治療用途、製剤、包装、使用パターン、投与部位、エンドユーザー、地域の観点から分析しています。また、市場の成長に影響を与える要因（促進要因、抑制要因、機会、課題）についても分析しています。市場における機会と課題を分析し、市場リーダー企業の競争環境の詳細を提供しています。さらに、マイクロマーケットを個々の成長傾向の観点から分析し、主要6地域および各国における市場セグメントの収益予測も示しています。

The injectable drug delivery devices market is projected to reach USD 373.7 billion by 2030 from USD 256.3 billion in 2025, at a CAGR of 7.8% during the forecast period. The injectable drug delivery formulations market is projected to reach USD 661.1 billion by 2030 from USD 434.0 billion in 2025, at a CAGR of 8.8% during the forecast period.

注射剤送達デバイス市場は、予測期間中に7.8%のCAGR（年平均成長率）で成長し、2025年の2,563億米ドルから2030年には3,737億米ドルに達すると予測されています。注射剤送達製剤市場は、予測期間中に8.8%のCAGRで成長し、2025年の4,340億米ドルから2030年には6,611億米ドルに達すると予測されています。

The injectable drug delivery market is experiencing rapid transformation due to the increasing demand for patient-centric, targeted, and minimally invasive treatment solutions. A significant trend in this market is the shift toward self-injection technologies, which include autoinjectors, pen injectors, and wearable injectors. These advancements enhance patient compliance and facilitate at-home care, which is especially important for managing chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis.

Technological advancements are increasingly shaping the market. Smart injectors equipped with connectivity features, dose tracking, and reminder systems are becoming more popular, reflecting the broader trend toward digital healthcare. Furthermore, the integration of microneedles and needle-free injectors is helping to reduce the pain and anxiety often associated with traditional syringes, particularly for pediatric and geriatric populations.

The pharmaceutical industry increasingly focuses on long-acting formulations, biologics, and biosimilars, requiring precise delivery systems. This trend is fostering closer collaboration between drug developers and device manufacturers. Additionally, regulatory bodies are updating their frameworks to better support combination products, which is helping to accelerate product approvals.

“By device, the self-injection devices segment is projected to grow at the highest CAGR during the forecast period.”

From 2025 to 2030, the self-injection devices segment is expected to grow at the highest rate within the injectable drug delivery market. This growth is driven by a global shift toward decentralized care, an increase in the prevalence of chronic diseases, and a growing emphasis on patient autonomy. Self-injection devices, which include autoinjectors, pen injectors, and wearable injectors, provide convenience and precision while reducing the need for clinical settings. This makes them particularly suitable for long-term therapies.

In the US and Canada, growth is driven by a high adoption rate of biologics for treating autoimmune and metabolic disorders, along with favorable reimbursement policies and the integration of digital technology in healthcare. Demand has increased significantly in Europe, particularly Germany, France, and the UK, due to the expanding geriatric population and well-structured chronic disease management programs. In the Asia Pacific region, countries such as Japan, China, and India are experiencing rapid growth due to improved healthcare access, increased patient awareness, and a rise in the availability of biosimilars.

Technological trends such as smart connectivity features, dose memory, and pain-reduction technologies make devices more appealing. The COVID-19 pandemic has also accelerated the adoption of self-care, as patients tend to avoid hospitals and prefer administering treatments at home. Collaborations between pharmaceutical companies and device manufacturers are increasing, allowing for customized solutions for injectable therapies. Overall, the rapid growth of this segment reflects a strong combination of clinical needs, patient preferences, and technological advancements.

“By formulation packaging, the ampoules segment accounted for the largest market share in 2024.”

The ampoules segment was the leading contributor to market share within the injectable drug delivery market in 2024. Ampoules are the fastest-growing packaging segment in this market, driven by their superior sterility, affordability, and adaptability to a wide range of drug formulations. Typically made of glass or plastic, ampoules are ideal for preserving single-dose injectable solutions without the risk of contamination, making them highly preferred in acute care and hospital settings.

In developing economies like India, Brazil, and Vietnam, the cost-effectiveness of ampoules encourages their widespread use in government vaccination and immunization programs. Additionally, their compatibility with various biologics and small-molecule drugs further facilitates adoption across therapeutic areas such as oncology, anti-infectives, and hormonal therapies.

“The Asia Pacific (APAC) region is expected to witness the highest growth rate during the forecast period.”

The Asia Pacific region is becoming the fastest-growing area in the injectable drug delivery market, driven by a combination of demographic, economic, and healthcare factors. The increasing prevalence of chronic diseases, particularly diabetes and cancer, in large countries like China and India, is creating a greater demand for advanced injectable therapies. Additionally, as access to biologics expands, there is an increased need for user-friendly devices, such as autoinjectors and pen injectors.

In China, supportive government policies, increasing investment in research and development, and a thriving biotechnology sector are driving the adoption of innovative drug delivery systems. Meanwhile, India, benefiting from a growing generics market, is also seeing significant growth in self-injection devices and biosimilars. Additionally, Southeast Asian countries like Vietnam and Thailand are enhancing their healthcare infrastructure and improving access to specialty care, which is boosting regional demand.

Urbanization, increasing disposable incomes, and a growing aging population contribute to the trend as patients and providers seek convenient, home-based treatment options. Additionally, regional manufacturing capabilities and cost-effective production attract partnerships from global pharmaceutical and device firms.

Breakdown of supply-side primary interviews:  • By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)  • By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)  • By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

• By Company Type: Hospitals (60%), Ambulatory Surgical Centers (25%), and Home Care Settings (15%)
• By Designation: Directors (35%), Vice Presidents (27%), Managers (22%), and Other Designations (16%)
• By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%)

Research Coverage

This report studies the injectable drug delivery market based on product, therapeutic application, formulation, packaging, usage pattern, site of administration, end user, and region. The report also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six main regions and respective countries.

Reasons to Buy the Report

The report can assist both established companies and new or smaller firms understand the market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below.

This report provides insights into the following points:

• Analysis of key drivers (increasing chronic diseases, increasing biologics, and technological advancements), restraints (infections associated with needle-stick injuries), challenges (other methods of injectable drug delivery available in the market), and opportunities (increasing demand for generic medicines and biosimilars) influencing the growth of injectable drug delivery market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the injectable drug delivery market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of injectable drug delivery procedures across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the injectable drug delivery market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the injectable drug delivery market.

Table of Contents

1               INTRODUCTION              72

1.1           STUDY OBJECTIVES       72

1.2           MARKET DEFINITION   72

1.3           MARKET SCOPE                73

1.3.1        MARKETS SEGMENTATION         73

1.3.2        REGIONAL SEGMENTATION       74

1.3.3        YEARS CONSIDERED      74

1.3.4        INCLUSIONS AND EXCLUSIONS 75

1.4           CURRENCY CONSIDERED            75

1.5           STAKEHOLDERS               76

1.6           SUMMARY OF CHANGES               76

2               RESEARCH METHODOLOGY       78

2.1           RESEARCH DATA              78

2.1.1        SECONDARY DATA          79

2.1.1.1    Key secondary sources         80

2.1.2        PRIMARY DATA 80

2.1.2.1    Primary sources    81

2.1.2.2    Key data from primary sources           82

2.1.2.3    Breakdown of primaries      83

2.2           MARKET SIZE ESTIMATION         84

2.2.1        APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH         85

2.2.2        APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION     86

2.2.3        APPROACH 3: TOP-DOWN APPROACH   87

2.2.4        APPROACH 4: BOTTOM-UP APPROACH 87

2.2.5        APPROACH 4: PRIMARY INTERVIEWS     88

2.2.6        APPROACH 5: DEMAND-SIDE APPROACH             88

2.2.7        APPROACH 6: VOLUME DATA ANALYSIS               88

2.3           DATA TRIANGULATION AND MARKET BREAKDOWN                 90

2.4           MARKET SHARE ASSESSMENT   90

2.5           RESEARCH ASSUMPTIONS           91

2.5.1        STUDY ASSUMPTIONS  91

2.5.2        GROWTH RATE ASSUMPTIONS 91

2.6           RESEARCH LIMITATIONS             91

2.7           RISK ASSESSMENT           92

3               EXECUTIVE SUMMARY  93

4               PREMIUM INSIGHTS       99

4.1           INJECTABLE DRUG DELIVERY MARKET OVERVIEW                 99

4.2           NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET OVERVIEW       100

4.3           INJECTABLE DRUG DELIVERY MARKET: REGIONAL MIX                 100

4.4           INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES      101

4.5           INJECTABLE DRUG DELIVERY MARKET: DEVELOPING VS. DEVELOPED MARKETS          101

5               MARKET OVERVIEW       102

5.1           MARKET DYNAMICS       102

5.1.1        DRIVERS               103

5.1.1.1    Growing demand for self-injection devices      103

5.1.1.2    Advancements in drug delivery technologies   103

5.1.1.3    Rising prevalence of chronic diseases                105

5.1.1.4    Growing adoption of biologics and biosimilars                106

5.1.2        RESTRAINTS      107

5.1.2.1    Infections associated with needlestick injuries 107

5.1.2.2    Stringent government regulations     107

5.1.3        OPPORTUNITIES              108

5.1.3.1    Development of novel drug delivery systems   108

5.1.3.2    Growing preference for home-based care devices           108

5.1.3.3    Growth opportunities in emerging economies 109

5.1.4        CHALLENGES    109

5.1.4.1    Alternative methods of drug delivery                 109

5.1.4.2    Complexities in developing wearable drug delivery systems                 110

5.2           INDUSTRY TRENDS         110

5.2.1        REUSABLE DRUG DELIVERY DEVICES    110

5.2.2        PREFILLED BIOLOGICS 110

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            111

5.4           PRICING ANALYSIS          112

5.4.1        AVERAGE SELLING PRICE TREND, BY KEY PLAYER                 112

5.4.1.1    Average selling price trend of key players, by device type                 112

5.4.1.2    Average selling price trend of key players, by pen injectors                 112

5.4.2        AVERAGE SELLING PRICE TREND, BY REGION   113

5.4.2.1    Average selling price trend of pen injectors, by region  113

5.4.2.2    Average selling price trend of needle-free injectors, by region                 114

5.4.2.3    Average selling price trend of autoinjectors, by region  114

5.4.2.4    Average selling price trend of wearable injectors, by region                 115

5.5           VALUE CHAIN ANALYSIS               115

5.5.1        RESEARCH & PRODUCT DEVELOPMENT               116

5.5.2        RAW MATERIAL PROCUREMENT               116

5.5.3        MANUFACTURING          116

5.5.4        MARKETING, SALES & DISTRIBUTION, AND AFTER-SALES SERVICES               116

5.6           SUPPLY CHAIN ANALYSIS             116

5.7           ECOSYSTEM ANALYSIS  117

5.8           INVESTMENT AND FUNDING SCENARIO               120

5.9           TECHNOLOGY ANALYSIS             120

5.9.1        KEY TECHNOLOGIES     120

5.9.1.1    Autoinjectors and smart injection devices        120

5.9.1.2    Needle-free injection systems and microneedle patches                 121

5.9.1.3    Wearable injectors for high-volume delivery   121

5.9.2        COMPLEMENTARY TECHNOLOGIES       122

5.9.2.1    Nanotechnology    122

5.9.2.2    Biodegradable polymers      122

5.9.3        ADJACENT TECHNOLOGIES       123

5.9.3.1    Artificial intelligence and digital therapeutics 123

5.9.3.2    Alternative routes of administration 123

5.10         PATENT ANALYSIS          124

5.10.1      PATENT PUBLICATION TRENDS FOR INJECTABLE DRUG DELIVERY              124

5.10.2      JURISDICTION AND TOP APPLICANT ANALYSIS                 125

5.11         TRADE ANALYSIS             126

5.11.1      TRADE DATA FOR HS CODE 901890          127

5.11.1.1  Import data            127

5.11.1.2  Export data            127

5.11.2      TRADE DATA FOR HS CODE 90183100      128

5.11.2.1  Import data            128

5.11.2.2  Export data            128

5.12         KEY CONFERENCES AND EVENTS, 2025–2026        129

5.13         CASE STUDY ANALYSIS 130

5.14         REGULATORY LANDSCAPE         132

5.14.1      REGULATORY ANALYSIS               132

5.14.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             133

5.15         PORTER’S FIVE FORCES ANALYSIS           136

5.15.1      BARGAINING POWER OF SUPPLIERS       136

5.15.2      BARGAINING POWER OF BUYERS             137

5.15.3      THREAT OF NEW ENTRANTS      137

5.15.4      THREAT OF SUBSTITUTES          137

5.15.5      INTENSITY OF COMPETITIVE RIVALRY 137

5.16         KEY STAKEHOLDERS AND BUYING CRITERIA     138

5.16.1      KEY STAKEHOLDERS     138

5.16.2      BUYING CRITERIA           138

5.16.2.1  Buying criteria for injectable drug delivery devices        138

5.16.2.2  Buying criteria for injectable drug delivery devices with formulations          139

5.17         PIPELINE ANALYSIS        140

5.18         REIMBURSEMENT ANALYSIS      149

5.19         UNMET NEEDS/END-USER EXPECTATIONS         149

5.20         IMPACT OF AI/GEN AI IN INJECTABLE DRUG DELIVERY MARKET               150

5.20.1      INTRODUCTION              150

5.20.2      MARKET POTENTIAL OF AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM 150

5.20.3      AI USE CASES     151

5.20.4      KEY COMPANIES IMPLEMENTING AI IN INJECTABLE DRUG DELIVERY DEVICES           152

5.20.5      FUTURE OF GEN AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM       152

5.21         IMPACT OF 2025 US TARIFF         153

5.21.1      INTRODUCTION              153

5.21.2      KEY TARIFF RATES          154

5.21.3      PRICE IMPACT ANALYSIS             155

5.21.4      IMPACT ON COUNTRY/REGION                155

5.21.4.1  North America      155

5.21.4.2  Asia Pacific            156

5.21.4.3  Europe   157

5.21.4.4  Latin America       157

5.21.5      IMPACT ON END-USE INDUSTRIES          158

6               INJECTABLE DRUG DELIVERY, BY PRODUCT      159

6.1           INTRODUCTION              160

6.2           DEVICES              162

6.2.1        CONVENTIONAL INJECTION DEVICES   166

6.2.1.1    By material             171

6.2.1.1.1 Glass injectable devices       171

6.2.1.1.1.1              Light protection, temperature resistance, and impermeability properties to drive market       171

6.2.1.1.2 Plastic injectable devices     174

6.2.1.1.2.1              Rapid increase in demand for syringes to aid growth                 174

6.2.1.2    By product             176

6.2.1.2.1 Fillable syringes    176

6.2.1.2.1.1              Ease of use and variable dosing formulations to boost market    176

6.2.1.2.2 Prefilled syringes  178

6.2.1.2.2.1              Minimal drug waste and low weight & space requirements to propel market           178

6.2.1.3    By usability            180

6.2.1.3.1 Reusable injection devices  180

6.2.1.3.1.1              Cost-effective nature to contribute to growth 180

6.2.1.3.2 Disposable injection devices               182

6.2.1.3.2.1              Growing preference for ready-to-use devices to drive market    182

6.2.2        SELF-INJECTION DEVICES           184

6.2.2.1    Needle-free injectors            188

6.2.2.1.1 By product             191

6.2.2.1.1.1              Fillable needle-free injectors               191

6.2.2.1.1.2              Prefilled needle-free injectors             193

6.2.2.1.2 By technology        195

6.2.2.1.2.1              Jet-based needle-free injectors           195

6.2.2.1.2.2              Spring-based needle-free injectors    197

6.2.2.1.2.3              Laser-powered needle-free injectors 199

6.2.2.1.2.4              Vibration-based needle-free injectors               201

6.2.2.1.3 By usability            202

6.2.2.1.3.1              Reusable needle-free injectors            202

6.2.2.1.3.2              Disposable needle-free injectors        204

6.2.2.2    Autoinjectors         206

6.2.2.2.1 By product             209

6.2.2.2.1.1              Fillable autoinjectors            209

6.2.2.2.1.2              Prefilled autoinjectors          211

6.2.2.2.2 By technology        213

6.2.2.2.2.1              Automated autoinjectors     213

6.2.2.2.2.2              Manual autoinjectors            215

6.2.2.2.3 By design                217

6.2.2.2.3.1              Standardized autoinjectors 217

6.2.2.2.3.2              Customized autoinjectors    219

6.2.2.2.4 By usability            221

6.2.2.2.4.1              Reusable autoinjectors         221

6.2.2.2.4.2              Disposable autoinjectors     223

6.2.2.3    Pen injectors         225

6.2.2.3.1 By product             228

6.2.2.3.1.1              Single-chambered pen injectors         228

6.2.2.3.1.2              Double-chambered pen injectors.     230

6.2.2.3.2 By design                232

6.2.2.3.2.1              Standard pen injectors         232

6.2.2.3.2.2              Customized pen injectors    234

6.2.2.3.3 By usability            236

6.2.2.3.3.1              Reusable pen injectors         236

6.2.2.3.3.2              Disposable pen injectors     238

6.2.2.4    Wearable injectors                240

6.2.2.4.1 Increasing need for safe and convenient injections to accelerate growth    240

6.2.2.5    Other self-injection devices                243

6.3           FORMULATIONS              245

6.3.1        CONVENTIONAL DRUG DELIVERY FORMULATIONS                 248

6.3.1.1    Solutions                251

6.3.1.1.1 High stability and sterility benefits to intensify growth 251

6.3.1.2    Reconstituted/lyophilized formulations            254

6.3.1.2.1 Higher suitability for parenteral administration to aid growth                 254

6.3.1.3    Suspensions           256

6.3.1.3.1 Innovations in injectable suspensions for stable and sustained delivery to aid growth           256

6.3.1.4    Emulsions              258

6.3.1.4.1 Advancements in injectable emulsions for controlled and sustained drug delivery to drive market            258

6.3.2        NOVEL DRUG DELIVERY FORMULATIONS           260

6.3.2.1    Colloidal dispersions            263

6.3.2.1.1 Niosomes               265

6.3.2.1.1.1              Low toxicity and economical features to speed up growth.   265

6.3.2.1.2 Liposomes              267

6.3.2.1.2.1              Flexible, biocompatible, and fully biodegradable properties to boost market  267

6.3.2.1.3 Polymeric/mixed micelles   269

6.3.2.1.3.1              Ability to deliver hydrophobic drugs with slower dissolution rates to boost market       269

6.3.2.1.4 Nanoparticles        271

6.3.2.1.4.1              Solid-lipid nanoparticles      273

6.3.2.1.4.2              Nanosuspensions 275

6.3.2.1.4.3              Nanoemulsions     277

6.3.2.2    Microparticles       279

6.3.2.2.1 Microspheres         281

6.3.2.2.1.1              Growing focus of major pharmaceutical companies on microsphere drug delivery to drive market       281

6.3.2.2.2 Microcapsules       283

6.3.2.2.2.1              Higher biocompatibility properties to augment growth                 283

6.3.3        LONG-ACTING INJECTABLE FORMULATIONS    285

6.3.3.1    Decreased side effects and overall medical cost reduction to advance growth     285

7               INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING      287

7.1           INTRODUCTION              288

7.2           AMPOULES         288

7.2.1        EASE OF TRANSPORTATION AND LOW MANUFACTURING COST TO AID GROWTH         288

7.3           VIALS    290

7.3.1        NEED FOR SECURE, DEPENDABLE, AND COST-EFFECTIVE CONTAINERS TO ENCOURAGE GROWTH      290

7.4           CARTRIDGES     292

7.4.1        INCREASING FOCUS ON DOSE ACCURACY AND PATIENT CONVENIENCE TO FACILITATE GROWTH        292

7.5           BOTTLES             294

7.5.1        RISING FOCUS ON SAFE STORAGE OF SOLUTIONS AND EMULSIONS TO FOSTER GROWTH           294

8               INJECTABLE DRUG DELIVERY, BY THERAPEUTIC APPLICATION   296

8.1           INTRODUCTION              297

8.2           AUTOIMMUNE DISEASES             297

8.2.1        RHEUMATOID ARTHRITIS           301

8.2.1.1    Increased focus on early-stage diagnosis and treatment to amplify growth    301

8.2.2        MULTIPLE SCLEROSIS   303

8.2.2.1    Increasing target patient pool to contribute to growth   303

8.2.3        CROHN’S DISEASE           305

8.2.3.1    Rising use of liposomes to aid growth                305

8.2.4        PSORIASIS           307

8.2.4.1    Lifestyle changes and high disease prevalence to support growth                 307

8.2.5        OTHER AUTOIMMUNE DISEASES             309

8.3           HORMONAL DISORDERS              311

8.3.1        DIABETES           314

8.3.1.1    Growing preference for self-injection devices over traditional syringes to drive market      314

8.3.2        REPRODUCTIVE HEALTH DISEASES       316

8.3.2.1    Lack of healthcare facilities and hygiene practices to aid growth                 316

8.3.3        ANTITHROMBOTIC/THROMBOLYTIC THERAPY                 318

8.3.3.1    High efficacy and safety of heparin for antithrombotic therapy to aid growth              318

8.3.4        OSTEOPOROSIS                320

8.3.4.1    Increasing number of women with calcium and vitamin D deficiencies to foster growth               320

8.3.5        GROWTH HORMONE DEFICIENCY           322

8.3.5.1    Increased need for daily injections of recombinant human growth hormones to fuel market     322

8.4           OBESITY              324

8.4.1        CHANGING SEDENTARY LIFESTYLE AND CONSUMPTION OF OVER-PROCESSED FOODS TO AID GROWTH                 324

8.5           CANCER                326

8.5.1        INCREASING LAUNCHES OF NEW VACCINES AND TARGETED THERAPIES TO BOLSTER GROWTH 326

8.6           INFECTIOUS DISEASES 329

8.6.1        GROWING ADVANCEMENTS IN INJECTABLE THERAPIES TO DRIVE MARKET         329

8.7           ORPHAN DISEASES         331

8.7.1        FAVORABLE GOVERNMENT INITIATIVES TO AUGMENT GROWTH             331

8.8           OTHER THERAPEUTIC APPLICATIONS  333

8.8.1        PAIN MANAGEMENT      334

8.8.1.1    Growing focus on treating chronic pain to drive market                 334

8.8.2        ALLERGIES          337

8.8.2.1    Increasing prevalence of asthma and eczema to promote growth                 337

8.8.3        AESTHETIC TREATMENTS           339

8.8.3.1    Growing popularity of aesthetic procedures to propel market                 339

8.8.4        HEPATITIS C      341

8.8.4.1    Need to curb virus spread due to needle reshare to sustain growth                 341

8.8.5        HEMOPHILIA     343

8.8.5.1    Increasing need for preventive treatment plans to assist growth                 343

9               INJECTABLE DRUG DELIVERY, BY USAGE PATTERN                 345

9.1           INTRODUCTION              346

9.2           CURATIVE CARE               346

9.2.1        RISE IN INFECTIOUS DISEASES TO ACCELERATE GROWTH             346

9.3           IMMUNIZATION               348

9.3.1        GROWING DEMAND FOR VACCINES FROM HEALTHCARE ORGANIZATIONS TO DRIVE MARKET       348

9.4           OTHER USAGE PATTERNS           350

10            INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION          352

10.1         INTRODUCTION              353

10.2         DERMAL-BASED ADMINISTRATION        353

10.2.1      RAPID AND EFFECTIVE METHOD WITH LOW PAIN TO AMPLIFY GROWTH          353

10.3         CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION          356

10.3.1      HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT GROWTH        356

10.4         ORGAN-BASED ADMINISTRATION           359

10.4.1      GROWING UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST MARKET               359

10.5         CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION                 361

10.5.1      INCREASING FOCUS ON PAIN MANAGEMENT TO PROMOTE GROWTH      361

11            INJECTABLE DRUG DELIVERY MARKET, BY END USER                 363

11.1         INTRODUCTION              364

11.2         HOSPITALS & CLINICS   364

11.2.1      RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH      364

11.3         HOME CARE SETTINGS 366

11.3.1      GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET             366

11.4         LONG-TERM CARE SETTINGS    368

11.4.1      BOOMING ELDERLY POPULATION AND BURDEN OF CHRONIC DISEASES TO EXPEDITE GROWTH      368

11.5         NURSING HOMES             370

11.5.1      GLOBAL SHIFT TOWARD AGED POPULATION TO STIMULATE GROWTH   370

11.6         OTHER END USERS         372

12            INJECTABLE DRUG DELIVERY MARKET, BY REGION                 374

12.1         INTRODUCTION              375

12.2         NORTH AMERICA             376

12.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 376

12.2.2      US           391

12.2.2.1  Increasing prevalence of chronic diseases to expedite growth                 391

12.2.3      CANADA               404

12.2.3.1  Growing preference for self-injection devices to drive market                 404

12.3         EUROPE               417

12.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      417

12.3.2      GERMANY           430

12.3.2.1  High healthcare spending to propel growth     430

12.3.3      UK          443

12.3.3.1  Rising cases of obesity and diabetes to promote growth                 443

12.3.4      FRANCE                456

12.3.4.1  Favorable health insurance system to accelerate growth                 456

12.3.5      SPAIN    469

12.3.5.1  Favorable healthcare regulations support growth            469

12.3.6      ITALY    481

12.3.6.1  Regional variation in terms of coverage and benefits to hinder growth    481

12.3.7      NETHERLANDS 494

12.3.7.1  Growing focus on enhanced patient care to drive market                 494

12.3.8      REST OF EUROPE             508

12.4         ASIA PACIFIC     521

12.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 521

12.4.2      CHINA  536

12.4.2.1  Large patient population and healthcare infrastructure improvements to augment growth     536

12.4.3      JAPAN   548

12.4.3.1  Supportive reimbursement policies and universal healthcare coverage to aid growth         548

12.4.4      INDIA    561

12.4.4.1  Rising diabetes and cardiovascular disease burden to propel market    561

12.4.5      AUSTRALIA         574

12.4.5.1  Increased patient volume to contribute to growth           574

12.4.6      SOUTH KOREA  587

12.4.6.1  Rising incidence of obesity and hypertension to amplify growth                 587

12.4.7      THAILAND          600

12.4.7.1  Expanding self-administration options to support growth                 600

12.4.8      VIETNAM             612

12.4.8.1  Rising investments and regulatory reforms to support market growth    612

12.4.9      REST OF ASIA PACIFIC   625

12.5         LATIN AMERICA                638

12.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 638

12.5.2      BRAZIL 652

12.5.2.1  Surge in obesity issues to stimulate growth      652

12.5.3      MEXICO                664

12.5.3.1  Increasing incidence of chronic diseases to drive market                 664

12.5.4      REST OF LATIN AMERICA             677

12.6         MIDDLE EAST & AFRICA                690

12.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 690

12.6.2      GCC COUNTRIES              703

12.6.2.1  Saudi Arabia          717

12.6.2.1.1                Healthcare reforms to contribute to growth     717

12.6.2.2  United Arab Emirates (UAE)             730

12.6.2.2.1                Growing infrastructure investments to drive market                 730

12.6.2.3  Rest of GCC Countries        743

12.6.3      REST OF MIDDLE EAST & AFRICA             756

13            COMPETITIVE LANDSCAPE         769

13.1         OVERVIEW          769

13.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            769

13.3         REVENUE ANALYSIS, 2020–2024  771

13.3.1      INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS           771

13.3.2      INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS           772

13.4         MARKET SHARE ANALYSIS, 2024                 773

13.4.1      INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS           773

13.4.2      INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS           775

13.5         BRAND/PRODUCT COMPARISON             778

13.6         R&D EXPENDITURE OF KEY PLAYERS     778

13.7         COMPANY VALUATION AND FINANCIAL METRICS                 779

13.7.1      COMPANY VALUATION 779

13.7.2      FINANCIAL METRICS      779

13.8         INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024  780

13.8.1      STARS   780

13.8.2      EMERGING LEADERS     780

13.8.3      PERVASIVE PLAYERS      780

13.8.4      PARTICIPANTS 780

13.8.5      INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT, 2024      782

13.8.5.1  Company footprint               782

13.8.5.2  Region footprint   783

13.8.5.3  Product type footprint         783

13.8.5.4  Usage pattern footprint       784

13.8.5.5  Therapeutic application footprint      785

13.8.5.6  Site of administration footprint          786

13.9         INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024                 787

13.9.1      PROGRESSIVE COMPANIES         787

13.9.2      RESPONSIVE COMPANIES            787

13.9.3      DYNAMIC COMPANIES  787

13.9.4      STARTING BLOCKS         787

13.9.5      INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024                 789

13.9.5.1  Detailed list of key startups/SMEs    789

13.9.5.2  Competitive benchmarking of startups/SMES                790

13.10       INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024                 790

13.10.1   STARS   791

13.10.2   EMERGING LEADERS     791

13.10.3   PERVASIVE PLAYERS      791

13.10.4   PARTICIPANTS 791

13.10.5   INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT, 2024  793

13.10.5.1                 Company footprint               793

13.10.5.2                 Region footprint   794

13.10.5.3                 Product type footprint         795

13.10.5.4                 Formulation packaging type footprint               796

13.10.5.5                 Therapeutic application footprint      797

13.10.5.6                 Site of administration footprint          798

13.11       INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023        799

13.11.1   PROGRESSIVE COMPANIES         799

13.11.2   RESPONSIVE COMPANIES            799

13.11.3   DYNAMIC COMPANIES  799

13.11.4   STARTING BLOCKS         799

13.11.5   INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2024   801

13.11.5.1                 Detailed list of key startups/SMEs    801

13.11.5.2                 Competitive benchmarking of startups/SMEs 802

13.12       COMPETITIVE SCENARIO             802

13.12.1   PRODUCT LAUNCHES AND APPROVALS               802

13.12.2   DEALS  803

13.12.3   EXPANSIONS     805

14            COMPANY PROFILES: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS          806

14.1         KEY PLAYERS     806

14.1.1      CARDINAL HEALTH        806

14.1.1.1  Business overview 806

14.1.1.2  Products offered   807

14.1.1.3  Recent developments           808

14.1.1.3.1                Expansions             808

14.1.1.4  MnM view              808

14.1.1.4.1                Right to win           808

14.1.1.4.2                Strategic choices   808

14.1.1.4.3                Weaknesses and competitive threats 809

14.1.2      BD          810

14.1.2.1  Business overview 810

14.1.2.2  Products offered   811

14.1.2.3  Recent developments           814

14.1.2.3.1                Deals      814

14.1.2.3.2                Expansions             815

14.1.2.4  MnM view              815

14.1.2.4.1                Right to win           815

14.1.2.4.2                Strategic choices   815

14.1.2.4.3                Weaknesses and competitive threats 815

14.1.3      B. BRAUN SE       816

14.1.3.1  Business overview 816

14.1.3.2  Products offered   817

14.1.3.3  MnM view              819

14.1.3.3.1                Right to win           819

14.1.3.3.2                Strategic choices   819

14.1.3.3.3                Weaknesses and competitive threats 819

14.1.4      BAXTER                820

14.1.4.1  Business overview 820

14.1.4.2  Products offered   821

14.1.4.3  Recent developments           822

14.1.4.3.1                Product launches and approvals         822

14.1.4.4  MnM view              823

14.1.4.4.1                Right to win           823

14.1.4.4.2                Strategic choices   823

14.1.4.4.3                Weaknesses and competitive threats 823

14.1.5      TERUMO CORPORATION             824

14.1.5.1  Business overview 824

14.1.5.2  Products offered   825

14.1.5.3  Recent developments           826

14.1.5.3.1                Product launches and approvals         826

14.1.5.3.2                Expansions             827

14.1.5.4  MnM view              827

14.1.5.4.1                Right to win           827

14.1.5.4.2                Strategic choices   827

14.1.5.4.3                Weaknesses and competitive threats 827

14.1.6      PHILLIPS-MEDSIZE CORPORATION (MOLEX)     828

14.1.6.1  Business overview 828

14.1.6.2  Products offered   828

14.1.6.3  Recent developments           829

14.1.6.3.1                Product launches and approvals         829

14.1.6.3.2                Deals      829

14.1.6.3.3                Expansions             829

14.1.7      NIPRO   830

14.1.7.1  Business overview 830

14.1.7.2  Products offered   831

14.1.7.3  Recent developments           832

14.1.7.3.1                Expansions             832

14.1.8      ICU MEDICAL, INC.          833

14.1.8.1  Business overview 833

14.1.8.2  Products offered   834

14.1.8.3  Recent developments           835

14.1.8.3.1                Deals      835

14.1.9      WEST PHARMACEUTICAL SERVICES, INC.             836

14.1.9.1  Business overview 836

14.1.9.2  Products offered   837

14.1.9.3  Recent developments           838

14.1.9.3.1                Deals      838

14.1.9.3.2                Expansions             838

14.1.10   GERRESHEIMER AG         840

14.1.10.1                 Business overview 840

14.1.10.2                 Products offered   841

14.1.10.3                 Recent developments           843

14.1.10.3.1             Product launches and approvals         843

14.1.10.3.2             Deals      843

14.1.10.3.3             Expansions             844

14.1.11   STEVANATO      845

14.1.11.1                 Business overview 845

14.1.11.2                 Products offered   846

14.1.11.3                 Recent developments           847

14.1.11.3.1             Product launches and approvals         847

14.1.11.3.2             Deals      847

14.1.11.3.3             Expansions             848

14.1.12   SCHOTT PHARMA            849

14.1.12.1                 Business overview 849

14.1.12.2                 Products offered   850

14.1.12.3                 Recent developments           851

14.1.12.3.1             Product launches and approvals         851

14.1.12.3.2             Deals      851

14.1.12.3.3             Expansions             852

14.1.13   MEDMIX               853

14.1.13.1                 Business overview 853

14.1.13.2                 Products offered   854

14.1.13.3                 Recent developments           855

14.1.13.3.1             Product launches and approvals         855

14.1.13.3.2             Deals      855

14.1.14   SOLM    856

14.1.14.1                 Business overview 856

14.1.14.2                 Products offered   856

14.1.15   YPSOMED            858

14.1.15.1                 Business overview 858

14.1.15.2                 Products offered   859

14.1.15.3                 Recent developments           860

14.1.15.3.1             Deals      860

14.1.15.3.2             Expansions             861

14.2         OTHER PLAYERS              862

14.2.1      OWEN MUMFORD            862

14.2.2      HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.                 863

14.2.3      POLYMEDICURE               864

14.2.4      UNION MEDICO INC.     865

14.2.5      SHL MEDICAL   866

14.2.6      ELCAM MEDICAL             867

15            COMPANY PROFILES: INJECTABLE DRUG DELIVERY

FORMULATION MANUFACTURERS          868

15.1         KEY PLAYERS     868

15.1.1      JOHNSON & JOHNSON SERVICES, INC.   868

15.1.1.1  Business overview 868

15.1.1.2  Products offered   869

15.1.1.3  Recent developments           871

15.1.1.3.1                Product launches and approvals         871

15.1.1.3.2                Deals      873

15.1.1.4  MnM view              873

15.1.1.4.1                Right to win           873

15.1.1.4.2                Strategic choices   873

15.1.1.4.3                Weaknesses and competitive threats 873

15.1.2      F. HOFFMANN-LA ROCHE LTD  874

15.1.2.1  Business overview 874

15.1.2.2  Products offered   875

15.1.2.3  Recent developments           877

15.1.2.3.1                Product launches and approvals         877

15.1.2.4  MnM view              879

15.1.2.4.1                Right to win           879

15.1.2.4.2                Strategic choices   879

15.1.2.4.3                Weaknesses and competitive threats 879

15.1.3      PFIZER INC.        880

15.1.3.1  Business overview 880

15.1.3.2  Products offered   881

15.1.3.3  Recent developments           887

15.1.3.3.1                Product launches and approvals         887

15.1.3.3.2                Deals      888

15.1.3.4  MnM view              889

15.1.3.4.1                Right to win           889

15.1.3.4.2                Strategic choices   889

15.1.3.4.3                Weaknesses and competitive threats 889

15.1.4      MERCK & CO., INC.          890

15.1.4.1  Business overview 890

15.1.4.2  Products offered   891

15.1.4.3  Recent developments           893

15.1.4.3.1                Product launches and approvals         893

15.1.4.3.2                Deals      895

15.1.4.3.3                Expansions             896

15.1.4.4  MnM view              896

15.1.4.4.1                Right to win           896

15.1.4.4.2                Strategic choices   896

15.1.4.4.3                Weaknesses and competitive threats 897

15.1.5      NOVARTIS AG   898

15.1.5.1  Business overview 898

15.1.5.2  Products offered   899

15.1.5.3  Recent developments           900

15.1.5.3.1                Product launches and approvals         900

15.1.5.3.2                Deals      901

15.1.5.3.3                Expansions             902

15.1.5.4  MnM view              902

15.1.5.4.1                Right to win           902

15.1.5.4.2                Strategic choices   902

15.1.5.4.3                Weaknesses and competitive threats 902

15.1.6      BAYER AG            903

15.1.6.1  Business overview 903

15.1.6.2  Products offered   904

15.1.6.3  Recent developments           905

15.1.6.3.1                Product launches and approvals         905

15.1.6.3.2                Expansions             906

15.1.7      ASTRAZENECA  907

15.1.7.1  Business overview 907

15.1.7.2  Products offered   908

15.1.7.3  Recent developments           909

15.1.7.3.1                Product launches and approvals         909

15.1.7.3.2                Deals      914

15.1.7.3.3                Expansions             915

15.1.8      TAKEDA PHARMACEUTICAL COMPANY LIMITED.                 916

15.1.8.1  Business overview 916

15.1.8.2  Products offered   917

15.1.8.3  Recent developments           919

15.1.8.3.1                Product launches and approvals         919

15.1.8.3.2                Deals      921

15.1.8.3.3                Expansions             922

15.1.9      ELI LILLY AND COMPANY            923

15.1.9.1  Business overview 923

15.1.9.2  Products offered   924

15.1.9.3  Recent developments           925

15.1.9.3.1                Product launches and approvals         925

15.1.9.3.2                Expansions             926

15.1.10   AMGEN INC.       929

15.1.10.1                 Business overview 929

15.1.10.2                 Products offered   930

15.1.10.3                 Recent developments           931

15.1.10.3.1             Product launches and approvals         931

15.1.10.3.2             Deals      932

15.1.10.3.3             Expansions             932

15.1.11   NOVO NORDISK A/S       934

15.1.11.1                 Business overview 934

15.1.11.2                 Products offered   935

15.1.11.3                 Recent developments           936

15.1.11.3.1             Product launches and approvals         936

15.1.11.3.2             Deals      937

15.1.11.3.3             Expansions             937

15.1.12   REGENERON PHARMACEUTICALS INC. 939

15.1.12.1                 Business overview 939

15.1.12.2                 Products offered   940

15.1.12.2.1             Product launches and approvals         940

15.1.12.2.2             Deals      942

15.1.13   FRESENIUS KABI AG        943

15.1.13.1                 Business overview 943

15.1.13.2                 Products offered   944

15.1.13.3                 Recent developments           945

15.1.13.3.1             Product launches and approvals         945

15.1.14   UCB S.A.               946

15.1.14.1                 Business overview 946

15.1.14.2                 Products offered   947

15.1.14.3                 Recent developments           948

15.1.14.3.1             Product launches and approvals         948

15.1.15   BIO-THERA SOLUTIONS, LTD.   949

15.1.15.1                 Business overview 949

15.1.15.2                 Products offered   950

15.1.15.3                 Recent developments           950

15.1.15.3.1             Product launches and approvals         950

15.2         OTHER PLAYERS              951

15.2.1      SAGENT                951

15.2.2      VALNEVA SE       954

15.2.3      XERIS PHARMACEUTICALS, INC.               955

15.2.4      PHARMAESSENTIA CORPORATION          956

15.2.5      HERON THERAPEUTICS, INC.     957

16            APPENDIX           958

16.1         DISCUSSION GUIDE        958

16.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                963

16.3         RELATED REPORTS         965

16.4         AUTHOR DETAILS           966

LIST OF TABLES

TABLE 1                INJECTABLE DRUG DELIVERY MARKET: INCLUSIONS AND EXCLUSIONS 75

TABLE 2                STANDARD CURRENCY CONVERSION RATES (UNIT OF USD), 2021–2024             75

TABLE 3                INJECTABLE DRUG DELIVERY MARKET: STUDY ASSUMPTIONS  91

TABLE 4                INJECTABLE DRUG DELIVERY MARKET: RISK ASSESSMENT     92

TABLE 5                APPROVALS FOR AUTOINJECTOR BIOLOGICS BY US FDA, 2024                 104

TABLE 6                KEY DEVELOPMENTS IN PREFILLED SYRINGES AND PEN INJECTORS, 2024–2025                 104

TABLE 7                KEY BIOSIMILARS/GENERICS WITH INJECTABLE DRUG DELIVERY DEVICES           106

TABLE 8                AVERAGE SELLING PRICE TREND OF KEY PLAYER, BY DEVICE TYPE,

2022–2024 (USD)                112

TABLE 9                AVERAGE SELLING PRICE TREND OF PEN INJECTORS, BY REGION,

2022–2024 (USD)                114

TABLE 10              AVERAGE SELLING PRICE TREND OF NEEDLE-FREE INJECTORS, BY REGION,

2022–2024 (USD)                114

TABLE 11              AVERAGE SELLING PRICE TREND OF AUTOINJECTORS, BY REGION,

2022–2024 (USD)                114

TABLE 12              AVERAGE SELLING PRICE TREND OF WEARABLE INJECTORS, BY REGION,

2022–2024 (USD)                115

TABLE 13              INJECTABLE DRUG DELIVERY DEVICE PROVIDERS: ROLE OF COMPANIES

IN ECOSYSTEM 119

TABLE 14              INJECTABLE DRUG DELIVERY FORMULATION PROVIDERS: ROLE OF COMPANIES

IN ECOSYSTEM 119

TABLE 15              INJECTABLE DRUG DELIVERY MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2025                 125

TABLE 16              IMPORT DATA FOR HS CODE 901890 (INCLUDING AUTOINJECTORS), BY COUNTRY, 2021–2024 (USD THOUSAND)      127

TABLE 17              EXPORT DATA FOR HS CODE 901890 (INCLUDING AUTOINJECTORS), BY COUNTRY, 2021–2024 (USD THOUSAND)      127

TABLE 18              IMPORT DATA FOR HS CODE 90183100 (INCLUDING PREFILLED SYRINGES),

BY COUNTRY, 2021–2024 (USD THOUSAND)         128

TABLE 19              EXPORT DATA FOR HS CODE 90183100 (INCLUDING PREFILLED SYRINGES),

BY COUNTRY, 2021–2024 (USD THOUSAND)         128

TABLE 20              INJECTABLE DRUG DELIVERY MARKET: KEY CONFERENCES AND EVENTS,

2025–2026              129

TABLE 21              CASE STUDY 1: DEVELOPMENT OF CLASS III DRUG DELIVERY SYSTEM FOR CHEMOTHERAPY               130

TABLE 22              CASE STUDY 2: DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION          131

TABLE 23              CASE STUDY 3: ADOPTION OF PEN INJECTOR PLATFORMS FOR IMPROVED THERAPEUTIC OUTCOMES                 131

TABLE 24              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 133

TABLE 25              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           133

TABLE 26              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 134

TABLE 27              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 134

TABLE 28              MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 135

TABLE 29              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 135

TABLE 30              INJECTABLE DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS           136

TABLE 31              INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)    138

TABLE 32              INJECTABLE DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE, 2023–2027  140

TABLE 33              US ADJUSTED RECIPROCAL TARIFF RATES, 2024                 154

TABLE 34              KEY PRODUCT-RELATED TARIFF EFFECTIVE INJECTABLE DRUG DELIVERY DEVICES 154

TABLE 35              NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS         155

TABLE 36              ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS          156

TABLE 37              EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS 157

TABLE 38              LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS         157

TABLE 39              INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             160

TABLE 40              INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      161

TABLE 41              KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY DEVICES        162

TABLE 42              INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             164

TABLE 43              INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             165

TABLE 44              KEY PLAYERS PROVIDING CONVENTIONAL INJECTION DEVICES      166

TABLE 45              CONVENTIONAL INJECTION DEVICES MARKET, BY REGION,

2023–2030 (THOUSAND UNITS)  168

TABLE 46              CONVENTIONAL INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             169

TABLE 47              CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             170

TABLE 48              CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             171

TABLE 49              KEY PLAYERS PROVIDING GLASS INJECTABLE DEVICES              172

TABLE 50              GLASS INJECTABLE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      173

TABLE 51              KEY PLAYERS PROVIDING PLASTIC INJECTABLE DEVICES              174

TABLE 52              PLASTIC INJECTABLE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      175

TABLE 53              CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             176

TABLE 54              KEY PLAYERS PROVIDING FILLABLE SYRINGES                 176

TABLE 55              FILLABLE SYRINGES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)             177

TABLE 56              KEY PLAYERS PROVIDING PREFILLED SYRINGES                 178

TABLE 57              PREFILLED SYRINGES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)             179

TABLE 58              CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             180

TABLE 59              KEY PLAYERS PROVIDING REUSABLE INJECTION DEVICES      180

TABLE 60              REUSABLE INJECTABLE DEVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             181

TABLE 61              KEY PLAYERS PROVIDING DISPOSABLE INJECTION DEVICES      182

TABLE 62              DISPOSABLE INJECTABLE DEVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             183

TABLE 63              KEY PLAYERS PROVIDING SELF-INJECTION DEVICES              184

TABLE 64              SELF-INJECTION DEVICES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)  186

TABLE 65              SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)             186

TABLE 66              SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      187

TABLE 67              KEY PLAYERS PROVIDING NEEDLE-FREE INJECTORS         188

TABLE 68              NEEDLE-FREE INJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)  189

TABLE 69              NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      190

TABLE 70              NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      191

TABLE 71              KEY PLAYERS PROVIDING FILLABLE NEEDLE-FREE INJECTORS              191

TABLE 72              FILLABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             192

TABLE 73              KEY PLAYERS PROVIDING PREFILLED NEEDLE-FREE INJECTORS              193

TABLE 74              PREFILLED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             194

TABLE 75              NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             195

TABLE 76              KEY PLAYERS PROVIDING JET-BASED NEEDLE-FREE INJECTORS              195

TABLE 77              JET-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             196

TABLE 78              KEY PLAYERS PROVIDING SPRING-BASED NEEDLE-FREE INJECTORS            197

TABLE 79              SPRING-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             198

TABLE 80              KEY PLAYERS PROVIDING LASER-POWERED NEEDLE-FREE INJECTORS            199

TABLE 81              LASER-POWERED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             200

TABLE 82              VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             201

TABLE 83              NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     202

TABLE 84              KEY PLAYERS PROVIDING REUSABLE NEEDLE-FREE INJECTORS              202

TABLE 85              REUSABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             203

TABLE 86              KEY PLAYERS PROVIDING DISPOSABLE NEEDLE-FREE INJECTORS            204

TABLE 87              DISPOSABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             205

TABLE 88              KEY PLAYERS PROVIDING AUTOINJECTORS                 206

TABLE 89              AUTOINJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)             207

TABLE 90              AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)        208

TABLE 91              AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)        209

TABLE 92              KEY PLAYERS PROVIDING FILLABLE AUTOINJECTORS             209

TABLE 93              FILLABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      210

TABLE 94              KEY PLAYERS PROVIDING PREFILLED AUTOINJECTORS             211

TABLE 95              PREFILLED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      212

TABLE 96              AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             213

TABLE 97              KEY PLAYERS PROVIDING AUTOMATED AUTOINJECTORS             213

TABLE 98              AUTOMATED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      214

TABLE 99              KEY PLAYERS PROVIDING MANUAL AUTOINJECTORS             215

TABLE 100            MANUAL AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      216

TABLE 101            AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)        217

TABLE 102            KEY PLAYERS PROVIDING STANDARDIZED AUTOINJECTORS             217

TABLE 103            STANDARDIZED AUTOINJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             218

TABLE 104            KEY PLAYERS PROVIDING CUSTOMIZED AUTOINJECTORS             219

TABLE 105            CUSTOMIZED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      220

TABLE 106            AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)        221

TABLE 107            KEY PLAYERS PROVIDING REUSABLE AUTOINJECTORS             221

TABLE 108            REUSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      222

TABLE 109            KEY PLAYERS PROVIDING DISPOSABLE AUTOINJECTORS             223

TABLE 110            DISPOSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      224

TABLE 111            KEY PLAYERS PROVIDING PEN INJECTORS                 225

TABLE 112            PEN INJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)      226

TABLE 113            PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)        227

TABLE 114            PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)        228

TABLE 115            KEY PLAYERS PROVIDING SINGLE-CHAMBERED PEN INJECTORS                228

TABLE 116            SINGLE-CHAMBERED PEN INJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             229

TABLE 117            KEY PLAYERS PROVIDING DOUBLE-CHAMBERED PEN INJECTORS    230

TABLE 118            DOUBLE-CHAMBERED PEN INJECTORS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             231

TABLE 119            PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 232

TABLE 120            KEY PLAYERS PROVIDING STANDARD PEN INJECTORS         232

TABLE 121            STANDARD PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      233

TABLE 122            KEY PLAYERS PROVIDING CUSTOMIZED PEN INJECTORS         234

TABLE 123            CUSTOMIZED PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      235

TABLE 124            PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)        236

TABLE 125            KEY PLAYERS PROVIDING REUSABLE PEN INJECTORS         236

TABLE 126            REUSABLE PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      237

TABLE 127            KEY PLAYERS PROVIDING DISPOSABLE PEN INJECTORS         238

TABLE 128            DISPOSABLE PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      239

TABLE 129            KEY PLAYERS PROVIDING WEARABLE INJECTORS         240

TABLE 130            WEARABLE INJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)  241

TABLE 131            WEARABLE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)             242

TABLE 132            KEY PLAYERS PROVIDING OTHER SELF-INJECTION DEVICES      243

TABLE 133            OTHER SELF-INJECTION DEVICES MARKET, BY REGION,

2023–2030 (THOUSAND UNITS)  243

TABLE 134            OTHER SELF-INJECTION DEVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             244

TABLE 135            KEY PLAYERS PROVIDING FORMULATIONS                 245

TABLE 136            INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             246

TABLE 137            INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             247

TABLE 138            KEY PLAYERS PROVIDING CONVENTIONAL DRUG DELIVERY FORMULATIONS           248

TABLE 139            CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             249

TABLE 140            CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             250

TABLE 141            KEY PLAYERS PROVIDING SOLUTIONS  251

TABLE 142            INJECTABLE DRUG DELIVERY SOLUTIONS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             253

TABLE 143            KEY PLAYERS PROVIDING RECONSTITUTED/LYOPHILIZED FORMULATIONS          254

TABLE 144            RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             255

TABLE 145            KEY PLAYERS PROVIDING SUSPENSIONS                 256

TABLE 146            INJECTABLE DRUG DELIVERY SUSPENSIONS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             257

TABLE 147            KEY PLAYERS PROVIDING EMULSIONS 258

TABLE 148            INJECTABLE DRUG DELIVERY EMULSIONS MARKET, BY REGION,

2023–2030 (USD BILLION)             259

TABLE 149            KEY PLAYERS PROVIDING NOVEL DRUG DELIVERY FORMULATIONS        260

TABLE 150            NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             261

TABLE 151            NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             262

TABLE 152            KEY PLAYERS PROVIDING COLLOIDAL DISPERSIONS    263

TABLE 153            COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)             263

TABLE 154            COLLOIDAL DISPERSIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)      264

TABLE 155            INJECTABLE DRUG DELIVERY NIOSOMES MARKET, BY REGION,

2023–2030 (USD BILLION)             266

TABLE 156            KEY PLAYERS PROVIDING LIPOSOMES  267

TABLE 157            INJECTABLE DRUG DELIVERY LIPOSOMES MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             268

TABLE 158            KEY PLAYERS PROVIDING POLYMERIC/MIXED MICELLES            269

TABLE 159            INJECTABLE DRUG DELIVERY POLYMERIC/MIXED MICELLES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION)                270

TABLE 160            INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             271

TABLE 161            INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             272

TABLE 162            KEY PLAYERS PROVIDING SOLID-LIPID NANOPARTICLES             273

TABLE 163            INJECTABLE DRUG DELIVERY SOLID-LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)             274

TABLE 164            KEY PLAYERS PROVIDING NANOSUSPENSIONS                 275

TABLE 165            INJECTABLE DRUG DELIVERY NANOSUSPENSIONS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             276

TABLE 166            KEY PLAYERS PROVIDING NANOEMULSIONS                 277

TABLE 167            INJECTABLE DRUG DELIVERY NANOEMULSIONS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             278

TABLE 168            KEY PLAYERS PROVIDING MICROPARTICLES                 279

TABLE 169            INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             279

TABLE 170            INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             280

TABLE 171            KEY PLAYERS PROVIDING MICROSPHERES                 281

TABLE 172            INJECTABLE DRUG DELIVERY MICROSPHERES MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             282

TABLE 173            KEY PLAYERS PROVIDING MICROCAPSULES                 283

TABLE 174            INJECTABLE DRUG DELIVERY MICROCAPSULES MARKET, BY COUNTRY,

2023–2030 (USD BILLION)           284

TABLE 175            KEY PLAYERS PROVIDING LONG-ACTING FORMULATIONS              285

TABLE 176            LONG-ACTING INJECTABLE FORMULATIONS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             286

TABLE 177            INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING,

2023–2030 (USD BILLION)             288

TABLE 178            INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY COUNTRY,

2023–2030 (USD BILLION)             289

TABLE 179            INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY COUNTRY,

2023–2030 (USD BILLION)             291

TABLE 180            INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY COUNTRY,

2023–2030 (USD BILLION)             293

TABLE 181            INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY COUNTRY,

2023–2030 (USD BILLION)             295

TABLE 182            INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION,

2023–2030 (USD BILLION)             297

TABLE 183            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR AUTOIMMUNE DISEASES     298

TABLE 184            INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)                 299

TABLE 185            INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)             300

TABLE 186            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR RHEUMATOID ARTHRITIS   301

TABLE 187            INJECTABLE DRUG DELIVERY MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023–2030 (USD BILLION)             302

TABLE 188            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS

FOR MULTIPLE SCLEROSIS          303

TABLE 189            INJECTABLE DRUG DELIVERY MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023–2030 (USD BILLION)                 304

TABLE 190            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS

FOR CROHN’S DISEASE 305

TABLE 191            INJECTABLE DRUG DELIVERY MARKET FOR CROHN’S DISEASE, BY COUNTRY, 2023–2030 (USD BILLION)                 306

TABLE 192            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR PSORIASIS   307

TABLE 193            INJECTABLE DRUG DELIVERY MARKET FOR PSORIASIS, BY COUNTRY,

2023–2030 (USD BILLION)             308

TABLE 194            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS

FOR OTHER AUTOIMMUNE DISEASES   309

TABLE 195            INJECTABLE DRUG DELIVERY MARKET FOR OTHER AUTOIMMUNE DISEASES,

BY COUNTRY, 2023–2030 (USD BILLION)                310

TABLE 196            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS

FOR HORMONAL DISORDERS    311

TABLE 197            INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)                 312

TABLE 198            INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY COUNTRY, 2023–2030 (USD BILLION)             313

TABLE 199            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR DIABETES   314

TABLE 200            INJECTABLE DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY,

2023–2030 (USD BILLION)             315

TABLE 201            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR REPRODUCTIVE HEALTH DISEASES                 316

TABLE 202            INJECTABLE DRUG DELIVERY MARKET FOR REPRODUCTIVE HEALTH DISEASES,

BY COUNTRY, 2023–2030 (USD BILLION)                317

TABLE 203            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY               318

TABLE 204            INJECTABLE DRUG DELIVERY MARKET FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY, BY COUNTRY, 2023–2030 (USD BILLION)             319

TABLE 205            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OSTEOPOROSIS        320

TABLE 206            INJECTABLE DRUG DELIVERY MARKET FOR OSTEOPOROSIS, BY COUNTRY,

2023–2030 (USD BILLION)             321

TABLE 207            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR GROWTH HORMONE DEFICIENCY                 322

TABLE 208            INJECTABLE DRUG DELIVERY MARKET FOR GROWTH HORMONE DEFICIENCY,

BY COUNTRY, 2023–2030 (USD BILLION)                323

TABLE 209            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OBESITY      324

TABLE 210            INJECTABLE DRUG DELIVERY MARKET FOR OBESITY, BY COUNTRY,

2023–2030 (USD BILLION)             325

TABLE 211            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR CANCER       326

TABLE 212            INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY,

2023–2030 (USD BILLION)             328

TABLE 213            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR INFECTIOUS DISEASES          329

TABLE 214            INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)                 330

TABLE 215            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ORPHAN DISEASES 331

TABLE 216            INJECTABLE DRUG DELIVERY MARKET FOR ORPHAN DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)                 332

TABLE 217            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OTHER THERAPEUTIC APPLICATIONS 333

TABLE 218            INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             334

TABLE 219            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR PAIN MANAGEMENT               335

TABLE 220            INJECTABLE DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)                 336

TABLE 221            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ALLERGIES 337

TABLE 222            INJECTABLE DRUG DELIVERY MARKET FOR ALLERGIES, BY COUNTRY,

2023–2030 (USD BILLION)             338

TABLE 223            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR AESTHETIC TREATMENTS   339

TABLE 224            INJECTABLE DRUG DELIVERY MARKET FOR AESTHETIC TREATMENTS,

BY COUNTRY, 2023–2030 (USD BILLION)                340

TABLE 225            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS

FOR HEPATITIS C             341

TABLE 226            INJECTABLE DRUG DELIVERY MARKET FOR HEPATITIS C, BY COUNTRY,

2023–2030 (USD BILLION)             342

TABLE 227            KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HEMOPHILIA             343

TABLE 228            INJECTABLE DRUG DELIVERY MARKET FOR HEMOPHILIA, BY COUNTRY,

2023–2030 (USD BILLION)             344

TABLE 229            INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             346

TABLE 230            INJECTABLE DRUG DELIVERY MARKET FOR CURATIVE CARE, BY COUNTRY,

2023–2030 (USD BILLION)             347

TABLE 231            INJECTABLE DRUG DELIVERY MARKET FOR IMMUNIZATION, BY COUNTRY,

2023–2030 (USD BILLION)             349

TABLE 232            INJECTABLE DRUG DELIVERY MARKET FOR OTHER USAGE PATTERNS,

BY COUNTRY, 2023–2030 (USD BILLION)                351

TABLE 233            INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION,

2023–2030 (USD BILLION)             353

TABLE 234            KEY PLAYERS PROVIDING DERMAL-BASED ADMINISTRATION          354

TABLE 235            INJECTABLE DRUG DELIVERY MARKET FOR DERMAL-BASED ADMINISTRATION,

BY COUNTRY, 2023–2030 (USD BILLION)                355

TABLE 236            KEY PLAYERS PROVIDING CIRCULATORY/MUSCULOSKELETAL

SYSTEM-BASED ADMINISTRATION          356

TABLE 237            INJECTABLE DRUG DELIVERY MARKET FOR CIRCULATORY/MUSCULOSKELETAL-BASED ADMINISTRATION, BY COUNTRY, 2023–2030 (USD BILLION)                358

TABLE 238            KEY PLAYERS PROVIDING ORGAN-BASED ADMINISTRATION          359

TABLE 239            INJECTABLE DRUG DELIVERY MARKET FOR ORGAN-BASED ADMINISTRATION,

BY COUNTRY, 2023–2030 (USD BILLION)                360

TABLE 240            KEY PLAYERS PROVIDING CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION          361

TABLE 241            INJECTABLE DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION, BY COUNTRY, 2023–2030 (USD BILLION)      362

TABLE 242            INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 364

TABLE 243            INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD BILLION)                 365

TABLE 244            INJECTABLE DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION)                 367

TABLE 245            INJECTABLE DRUG DELIVERY MARKET FOR LONG-TERM CARE SETTINGS,

BY COUNTRY, 2023–2030 (USD BILLION)                369

TABLE 246            INJECTABLE DRUG DELIVERY MARKET FOR NURSING HOMES, BY COUNTRY, 2023–2030 (USD BILLION)                 371

TABLE 247            INJECTABLE DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)                 373

TABLE 248            INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION)           376

TABLE 249            NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             378

TABLE 250            NORTH AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)             378

TABLE 251            NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 378

TABLE 252            NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)                 379

TABLE 253            NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)                 379

TABLE 254            NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)                 379

TABLE 255            NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             380

TABLE 256            NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             380

TABLE 257            NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             381

TABLE 258            NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             381

TABLE 259            NORTH AMERICA: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             382

TABLE 260            NORTH AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             382

TABLE 261            NORTH AMERICA: AUTOINJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             382

TABLE 262            NORTH AMERICA: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             383

TABLE 263            NORTH AMERICA: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             383

TABLE 264            NORTH AMERICA: PEN INJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             383

TABLE 265            NORTH AMERICA: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             384

TABLE 266            NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)             384

TABLE 267            NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          385

TABLE 268            NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 385

TABLE 269            NORTH AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             386

TABLE 270            NORTH AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          386

TABLE 271            NORTH AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          386

TABLE 272            NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 387

TABLE 273            NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 387

TABLE 274            NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)             388

TABLE 275            NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)             388

TABLE 276            NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)          389

TABLE 277            NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)             389

TABLE 278            NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 390

TABLE 279            NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             390

TABLE 280            US: KEY MACROECONOMIC INDICATORS                 391

TABLE 281            US: INJECTABLE DRUG DELIVERY MARKET PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             392

TABLE 282            US: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             392

TABLE 283            US: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             392

TABLE 284            US: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             393

TABLE 285            US: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             393

TABLE 286            US: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 393

TABLE 287            US: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      394

TABLE 288            US: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             394

TABLE 289            US: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     394

TABLE 290            US: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             395

TABLE 291            US: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             395

TABLE 292            US: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             395

TABLE 293            US: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)             396

TABLE 294            US: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             396

TABLE 295            US: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)        396

TABLE 296            US: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)             397

TABLE 297            US: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             397

TABLE 298            US: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             398

TABLE 299            US: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             398

TABLE 300            US: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 399

TABLE 301            US: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             399

TABLE 302            US: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             399

TABLE 303            US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING,

2023–2030 (USD BILLION)             400

TABLE 304            US: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION,

2023–2030 (USD BILLION)             400

TABLE 305            US: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)                 401

TABLE 306            US: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)                 401

TABLE 307            US: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             402

TABLE 308            US: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             402

TABLE 309            US: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION,

2023–2030 (USD BILLION)             403

TABLE 310            US: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             403

TABLE 311            CANADA: KEY MACROECONOMIC INDICATORS                 404

TABLE 312            CANADA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             405

TABLE 313            CANADA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             405

TABLE 314            CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             405

TABLE 315            CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             406

TABLE 316            CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             406

TABLE 317            CANADA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)          406

TABLE 318            CANADA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             407

TABLE 319            CANADA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             407

TABLE 320            CANADA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             407

TABLE 321            CANADA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      408

TABLE 322            CANADA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             408

TABLE 323            CANADA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           408

TABLE 324            CANADA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     409

TABLE 325            CANADA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      409

TABLE 326            CANADA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             409

TABLE 327            CANADA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     410

TABLE 328            CANADA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             410

TABLE 329            CANADA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 411

TABLE 330            CANADA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             411

TABLE 331            CANADA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)          412

TABLE 332            CANADA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             412

TABLE 333            CANADA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 412

TABLE 334            CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)             413

TABLE 335            CANADA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             413

TABLE 336            CANADA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2030 (USD BILLION)        414

TABLE 337            CANADA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          414

TABLE 338            CANADA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             415

TABLE 339            CANADA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             415

TABLE 340            CANADA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)             416

TABLE 341            CANADA: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             416

TABLE 342            EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             418

TABLE 343            EUROPE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             418

TABLE 344            EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             419

TABLE 345            EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             419

TABLE 346            EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             419

TABLE 347            EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             420

TABLE 348            EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)          420

TABLE 349            EUROPE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             420

TABLE 350            EUROPE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             421

TABLE 351            EUROPE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             421

TABLE 352            EUROPE: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      421

TABLE 353            EUROPE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             422

TABLE 354          EUROPE: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             422

TABLE 355            EUROPE: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     422

TABLE 356            EUROPE: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      423

TABLE 357            EUROPE: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             423

TABLE 358            EUROPE: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     423

TABLE 359            EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             424

TABLE 360            EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 424

TABLE 361            EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             425

TABLE 362            EUROPE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)          425

TABLE 363            EUROPE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             425

TABLE 364            EUROPE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 426

TABLE 365            EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)             426

TABLE 366            EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             427

TABLE 367            EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          427

TABLE 368            EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          428

TABLE 369            EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             428

TABLE 370            EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             429

TABLE 371            EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)             429

TABLE 372            EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             430

TABLE 373            GERMANY: KEY MACROECONOMIC INDICATORS      431

TABLE 374            GERMANY: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             431

TABLE 375            GERMANY: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             431

TABLE 376            GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             432

TABLE 377            GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             432

TABLE 378            GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             432

TABLE 379            GERMANY: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             433

TABLE 380            GERMANY: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             433

TABLE 381            GERMANY: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             434

TABLE 382            GERMANY: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             434

TABLE 383            GERMANY: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      434

TABLE 384            GERMANY: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             435

TABLE 385            GERMANY: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           435

TABLE 386            GERMANY: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     435

TABLE 387            GERMANY: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      436

TABLE 388            GERMANY: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           436

TABLE 389            GERMANY: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     436

TABLE 390            GERMANY: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 437

TABLE 391            GERMANY: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 437

TABLE 392            GERMANY: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             438

TABLE 393            GERMANY: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             438

TABLE 394            GERMANY: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 438

TABLE 395            GERMANY: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 439

TABLE 396            GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)             439

TABLE 397            GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             440

TABLE 398            GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 440

TABLE 399            GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 441

TABLE 400            GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             441

TABLE 401            GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             442

TABLE 402            GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)             442

TABLE 403            GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             443

TABLE 404            UK: KEY MACROECONOMIC INDICATORS                 444

TABLE 405            UK: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             444

TABLE 406            UK: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             444

TABLE 407            UK: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             445

TABLE 408            UK: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             445

TABLE 409            UK: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             445

TABLE 410            UK: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 446

TABLE 411            UK: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      446

TABLE 412            UK: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             447

TABLE 413            UK: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     447

TABLE 414            UK: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             447

TABLE 415            UK: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             448

TABLE 416            UK: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             448

TABLE 417            UK: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)             448

TABLE 418            UK: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             449

TABLE 419            UK: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)        449

TABLE 420            UK: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)             449

TABLE 421            UK: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             450

TABLE 422            UK: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             450

TABLE 423            UK: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             451

TABLE 424            UK: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 451

TABLE 425            UK: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             451

TABLE 426            UK: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             452

TABLE 427            UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING,

2023–2030 (USD BILLION)             452

TABLE 428            UK: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION,

2023–2030 (USD BILLION)             453

TABLE 429            UK: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)                 453

TABLE 430            UK: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)                 454

TABLE 431            UK: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             454

TABLE 432            UK: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             455

TABLE 433            UK: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION,

2023–2030 (USD BILLION)             455

TABLE 434            UK: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             456

TABLE 435            FRANCE: KEY MACROECONOMIC INDICATORS                 456

TABLE 436            FRANCE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             457

TABLE 437            FRANCE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             457

TABLE 438            FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             457

TABLE 439            FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             458

TABLE 440            FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             458

TABLE 441            FRANCE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 458

TABLE 442            FRANCE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             459

TABLE 443            FRANCE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             459

TABLE 444            FRANCE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             459

TABLE 445            FRANCE: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      460

TABLE 446            FRANCE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             460

TABLE 447          FRANCE: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             460

TABLE 448            FRANCE: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     461

TABLE 449            FRANCE: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      461

TABLE 450            FRANCE: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             461

TABLE 451            FRANCE: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     462

TABLE 452            FRANCE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             462

TABLE 453            FRANCE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 463

TABLE 454            FRANCE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             463

TABLE 455            FRANCE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)          464

TABLE 456            FRANCE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             464

TABLE 457            FRANCE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 464

TABLE 458            FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)             465

TABLE 459            FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             465

TABLE 460            FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          466

TABLE 461            FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          466

TABLE 462            FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             467

TABLE 463            FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             467

TABLE 464            FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)             468

TABLE 465            FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             468

TABLE 466            SPAIN: KEY MACROECONOMIC INDICATORS                 469

TABLE 467            SPAIN: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             469

TABLE 468            SPAIN: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             470

TABLE 469            SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             470

TABLE 470            SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             470

TABLE 471            SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             471

TABLE 472            SPAIN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 471

TABLE 473            SPAIN: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             471

TABLE 474            SPAIN: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             472

TABLE 475            SPAIN: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             472

TABLE 476            SPAIN: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      472

TABLE 477            SPAIN: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             473

TABLE 478            SPAIN: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             473

TABLE 479            SPAIN: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     473

TABLE 480            SPAIN: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             474

TABLE 481            SPAIN: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             474

TABLE 482            SPAIN: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)             474

TABLE 483            SPAIN: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             475

TABLE 484            SPAIN: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 475

TABLE 485            SPAIN: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             476

TABLE 486            SPAIN: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 476

TABLE 487            SPAIN: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             476

TABLE 488            SPAIN: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             477

TABLE 489            SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 477

TABLE 490            SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 478

TABLE 491            SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          478

TABLE 492            SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          479

TABLE 493            SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 479

TABLE 494            SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             480

TABLE 495            SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 480

TABLE 496            SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             481

TABLE 497            ITALY: KEY MACROECONOMIC INDICATORS                 482

TABLE 498            ITALY: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             482

TABLE 499            ITALY: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             482

TABLE 500            ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             483

TABLE 501            ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             483

TABLE 502            ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             483

TABLE 503            ITALY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 484

TABLE 504            ITALY: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             484

TABLE 505            ITALY: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             485

TABLE 506            ITALY: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             485

TABLE 507            ITALY: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      485

TABLE 508            ITALY: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             486

TABLE 509            ITALY: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             486

TABLE 510            ITALY: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     486

TABLE 511            ITALY: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             487

TABLE 512            ITALY: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             487

TABLE 513            ITALY: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)             487

TABLE 514            ITALY: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             488

TABLE 515            ITALY: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             488

TABLE 516            ITALY: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             489

TABLE 517            ITALY: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 489

TABLE 518            ITALY: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             489

TABLE 519            ITALY: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             490

TABLE 520            ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 490

TABLE 521            ITALY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 491

TABLE 522            ITALY: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          491

TABLE 523            ITALY: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          492

TABLE 524            ITALY: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 492

TABLE 525            ITALY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             493

TABLE 526            ITALY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION,

2023–2030 (USD BILLION)             493

TABLE 527            ITALY: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             494

TABLE 528            NETHERLANDS: KEY MACROECONOMIC INDICATORS      495

TABLE 529            NETHERLANDS: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 495

TABLE 530            NETHERLANDS: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             495

TABLE 531            NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)                 496

TABLE 532            NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)                 496

TABLE 533            NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)                 496

TABLE 534            NETHERLANDS: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             497

TABLE 535            NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             497

TABLE 536            NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             498

TABLE 537            NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             498

TABLE 538            NETHERLANDS: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             499

TABLE 539            NETHERLANDS: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             499

TABLE 540            NETHERLANDS: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           499

TABLE 541            NETHERLANDS: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             500

TABLE 542            NETHERLANDS: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             500

TABLE 543            NETHERLANDS: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           500

TABLE 544            NETHERLANDS: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             501

TABLE 545            NETHERLANDS: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 501

TABLE 546            NETHERLANDS: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          502

TABLE 547            NETHERLANDS: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 502

TABLE 548            NETHERLANDS: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             503

TABLE 549            NETHERLANDS: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 503

TABLE 550            NETHERLANDS: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 503

TABLE 551            NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 504

TABLE 552            NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 504

TABLE 553            NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 505

TABLE 554            NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 505

TABLE 555            NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             506

TABLE 556            NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)                 506

TABLE 557            NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 507

TABLE 558            NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             507

TABLE 559            REST OF EUROPE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 508

TABLE 560            REST OF EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)   508

TABLE 561            REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)                 509

TABLE 562            REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)                 509

TABLE 563            REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)                 509

TABLE 564            REST OF EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             510

TABLE 565            REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             510

TABLE 566            REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             511

TABLE 567            REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             511

TABLE 568            REST OF EUROPE: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             512

TABLE 569            REST OF EUROPE: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             512

TABLE 570            REST OF EUROPE: AUTOINJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             512

TABLE 571            REST OF EUROPE: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             513

TABLE 572            REST OF EUROPE: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             513

TABLE 573            REST OF EUROPE: PEN INJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             513

TABLE 574            REST OF EUROPE: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             514

TABLE 575            REST OF EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          514

TABLE 576            REST OF EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          515

TABLE 577            REST OF EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 515

TABLE 578            REST OF EUROPE: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             516

TABLE 579            REST OF EUROPE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          516

TABLE 580            REST OF EUROPE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          516

TABLE 581            REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 517

TABLE 582            REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 517

TABLE 583            REST OF EUROPE: INJECTABLE DRUG DELIVERY FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          518

TABLE 584            REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 518

TABLE 585            REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             519

TABLE 586            REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)                 519

TABLE 587            REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 520

TABLE 588            REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             520

TABLE 589            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             523

TABLE 590            ASIA PACIFIC: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             523

TABLE 591            ASIA PACIFIC: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             524

TABLE 592            ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             524

TABLE 593            ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             524

TABLE 594            ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             525

TABLE 595            ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             525

TABLE 596            ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             525

TABLE 597            ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             526

TABLE 598            ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             526

TABLE 599            ASIA PACIFIC: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      527

TABLE 600            ASIA PACIFIC: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             527

TABLE 601            ASIA PACIFIC: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           527

TABLE 602            ASIA PACIFIC: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     528

TABLE 603            ASIA PACIFIC: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      528

TABLE 604            ASIA PACIFIC: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           528

TABLE 605            ASIA PACIFIC: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     529

TABLE 606            ASIA PACIFIC: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 529

TABLE 607            ASIA PACIFIC: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)             530

TABLE 608            ASIA PACIFIC: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             530

TABLE 609            ASIA PACIFIC: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             531

TABLE 610            ASIA PACIFIC: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 531

TABLE 611            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 531

TABLE 612            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 532

TABLE 613            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 532

TABLE 614            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 533

TABLE 615            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 533

TABLE 616            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             534

TABLE 617            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             534

TABLE 618            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)             535

TABLE 619            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             535

TABLE 620            CHINA: KEY MACROECONOMIC INDICATORS                 536

TABLE 621            CHINA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             536

TABLE 622            CHINA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             537

TABLE 623            CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             537

TABLE 624            CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             537

TABLE 625            CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             538

TABLE 626            CHINA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 538

TABLE 627            CHINA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             538

TABLE 628            CHINA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             539

TABLE 629            CHINA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             539

TABLE 630            CHINA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      539

TABLE 631            CHINA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             540

TABLE 632            CHINA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             540

TABLE 633            CHINA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     540

TABLE 634            CHINA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             541

TABLE 635            CHINA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             541

TABLE 636          CHINA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)             541

TABLE 637            CHINA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             542

TABLE 638            CHINA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 542

TABLE 639            CHINA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             543

TABLE 640            CHINA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 543

TABLE 641            CHINA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             543

TABLE 642            CHINA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             544

TABLE 643            CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 544

TABLE 644            CHINA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 545

TABLE 645            CHINA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          545

TABLE 646            CHINA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          546

TABLE 647            CHINA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 546

TABLE 648            CHINA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             547

TABLE 649            CHINA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 547

TABLE 650            CHINA: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             548

TABLE 651            JAPAN: KEY MACROECONOMIC INDICATORS                 549

TABLE 652            JAPAN: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             549

TABLE 653            JAPAN: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             549

TABLE 654            JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             550

TABLE 655            JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             550

TABLE 656            JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             550

TABLE 657            JAPAN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 551

TABLE 658            JAPAN: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             551

TABLE 659            JAPAN: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             552

TABLE 660            JAPAN: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             552

TABLE 661            JAPAN: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      552

TABLE 662            JAPAN: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             553

TABLE 663            JAPAN: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             553

TABLE 664            JAPAN: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     553

TABLE 665            JAPAN: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             554

TABLE 666            JAPAN: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             554

TABLE 667            JAPAN: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)             554

TABLE 668            JAPAN: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             555

TABLE 669            JAPAN: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 555

TABLE 670            JAPAN: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             556

TABLE 671            JAPAN: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 556

TABLE 672            JAPAN: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             556

TABLE 673            JAPAN: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             557

TABLE 674            JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 557

TABLE 675            JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 558

TABLE 676            JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          558

TABLE 677            JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          559

TABLE 678            JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 559

TABLE 679            JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             560

TABLE 680            JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 560

TABLE 681            JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             561

TABLE 682            INDIA: KEY MACROECONOMIC INDICATORS                 561

TABLE 683            INDIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             562

TABLE 684            INDIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             562

TABLE 685            INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             562

TABLE 686            INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             563

TABLE 687            INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             563

TABLE 688            INDIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 563

TABLE 689            INDIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             564

TABLE 690            INDIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             564

TABLE 691            INDIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             564

TABLE 692          INDIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             565

TABLE 693            INDIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             565

TABLE 694            INDIA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             565

TABLE 695            INDIA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     566

TABLE 696            INDIA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             566

TABLE 697            INDIA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             566

TABLE 698            INDIA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)             567

TABLE 699            INDIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             567

TABLE 700            INDIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             568

TABLE 701            INDIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             568

TABLE 702            INDIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 569

TABLE 703            INDIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             569

TABLE 704            INDIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             569

TABLE 705            INDIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 570

TABLE 706            INDIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 570

TABLE 707            INDIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          571

TABLE 708            INDIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          571

TABLE 709            INDIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 572

TABLE 710            INDIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             572

TABLE 711            INDIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 573

TABLE 712            INDIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             573

TABLE 713            AUSTRALIA: KEY MACROECONOMIC INDICATORS      574

TABLE 714            AUSTRALIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             574

TABLE 715            AUSTRALIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             575

TABLE 716            AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             575

TABLE 717            AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             575

TABLE 718            AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             576

TABLE 719          AUSTRALIA: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             576

TABLE 720          AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             576

TABLE 721          AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             577

TABLE 722          AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             577

TABLE 723            AUSTRALIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      578

TABLE 724            AUSTRALIA: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             578

TABLE 725            AUSTRALIA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           578

TABLE 726            AUSTRALIA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     579

TABLE 727            AUSTRALIA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      579

TABLE 728            AUSTRALIA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           579

TABLE 729            AUSTRALIA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     580

TABLE 730            AUSTRALIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 580

TABLE 731            AUSTRALIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 581

TABLE 732            AUSTRALIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             581

TABLE 733            AUSTRALIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             582

TABLE 734            AUSTRALIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 582

TABLE 735            AUSTRALIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 582

TABLE 736            AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)             583

TABLE 737            AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             583

TABLE 738            AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 584

TABLE 739            AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 584

TABLE 740            AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             585

TABLE 741            AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             585

TABLE 742            AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)             586

TABLE 743            AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             586

TABLE 744            SOUTH KOREA: KEY MACROECONOMIC INDICATORS      587

TABLE 745            SOUTH KOREA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, TYPE,

2023–2030 (USD BILLION)             588

TABLE 746            SOUTH KOREA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             588

TABLE 747            SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)                 588

TABLE 748            SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)                 589

TABLE 749            SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)                 589

TABLE 750            SOUTH KOREA: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             589

TABLE 751            SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             590

TABLE 752            SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             590

TABLE 753            SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             591

TABLE 754            SOUTH KOREA: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             591

TABLE 755            SOUTH KOREA: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             591

TABLE 756            SOUTH KOREA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           592

TABLE 757            SOUTH KOREA: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             592

TABLE 758            SOUTH KOREA: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             592

TABLE 759            SOUTH KOREA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           593

TABLE 760            SOUTH KOREA: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             593

TABLE 761            SOUTH KOREA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 593

TABLE 762            SOUTH KOREA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          594

TABLE 763            SOUTH KOREA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             594

TABLE 764            SOUTH KOREA: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             595

TABLE 765            SOUTH KOREA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 595

TABLE 766            SOUTH KOREA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 595

TABLE 767            SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 596

TABLE 768            SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 596

TABLE 769            SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 597

TABLE 770            SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 597

TABLE 771            SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             598

TABLE 772            SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)                 598

TABLE 773            SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 599

TABLE 774            SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             599

TABLE 775            THAILAND: KEY MACROECONOMIC INDICATORS      600

TABLE 776            THAILAND: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             600

TABLE 777            THAILAND: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             601

TABLE 778            THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             601

TABLE 779            THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             601

TABLE 780            THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             602

TABLE 781            THAILAND: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             602

TABLE 782            THAILAND: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             602

TABLE 783            THAILAND: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             603

TABLE 784            THAILAND: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             603

TABLE 785            THAILAND: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      603

TABLE 786            THAILAND: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             604

TABLE 787            THAILAND: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           604

TABLE 788            THAILAND: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     604

TABLE 789            THAILAND: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      605

TABLE 790            THAILAND: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           605

TABLE 791            THAILAND: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     605

TABLE 792            THAILAND: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 606

TABLE 793            THAILAND: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 606

TABLE 794            THAILAND: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             607

TABLE 795          THAILAND: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             607

TABLE 796            THAILAND: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 607

TABLE 797            THAILAND: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 608

TABLE 798            THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)             608

TABLE 799            THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             609

TABLE 800            THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 609

TABLE 801            THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          610

TABLE 802            THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             610

TABLE 803            THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             611

TABLE 804            THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)             611

TABLE 805            THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             612

TABLE 806            VIETNAM: KEY MACROECONOMIC INDICATORS                 613

TABLE 807            VIETNAM: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             613

TABLE 808            VIETNAM: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             613

TABLE 809            VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             614

TABLE 810            VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             614

TABLE 811            VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             614

TABLE 812            VIETNAM: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)          615

TABLE 813            VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             615

TABLE 814            VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             616

TABLE 815            VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             616

TABLE 816            VIETNAM: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      616

TABLE 817            VIETNAM: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             617

TABLE 818            VIETNAM: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           617

TABLE 819            VIETNAM: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     617

TABLE 820            VIETNAM: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      618

TABLE 821          VIETNAM: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             618

TABLE 822            VIETNAM: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     618

TABLE 823            VIETNAM: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             619

TABLE 824            VIETNAM: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 619

TABLE 825            VIETNAM: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             620

TABLE 826            VIETNAM: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             620

TABLE 827            VIETNAM: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 620

TABLE 828            VIETNAM: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 621

TABLE 829            VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)             621

TABLE 830            VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             622

TABLE 831            VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          622

TABLE 832            VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          623

TABLE 833            VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             623

TABLE 834            VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             624

TABLE 835            VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)             624

TABLE 836            VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             625

TABLE 837            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)             625

TABLE 838            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 626

TABLE 839            REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET,

BY MATERIAL, 2023–2030 (USD BILLION)               626

TABLE 840            REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET,

BY PRODUCT, 2023–2030 (USD BILLION)                626

TABLE 841            REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET,

BY USABILITY, 2023–2030 (USD BILLION)               627

TABLE 842            REST OF ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             627

TABLE 843            REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             627

TABLE 844            REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             628

TABLE 845            REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             628

TABLE 846            REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             629

TABLE 847            REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             629

TABLE 848            REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             629

TABLE 849            REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             630

TABLE 850          REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             630

TABLE 851          REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             630

TABLE 852          REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             631

TABLE 853            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          631

TABLE 854            REST OF ASIA PACIFIC: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)             632

TABLE 855            REST OF ASIA PACIFIC: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 632

TABLE 856            REST OF ASIA PACIFIC: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             633

TABLE 857            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          633

TABLE 858            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)             633

TABLE 859            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 634

TABLE 860            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 634

TABLE 861            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)             635

TABLE 862            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)             635

TABLE 863            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)          636

TABLE 864            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)             636

TABLE 865            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 637

TABLE 866            REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)                 637

TABLE 867            LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             639

TABLE 868            LATIN AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 639

TABLE 869            LATIN AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             639

TABLE 870            LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)                 640

TABLE 871            LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)                 640

TABLE 872            LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)                 640

TABLE 873            LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             641

TABLE 874            LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             641

TABLE 875            LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             642

TABLE 876            LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             642

TABLE 877            LATIN AMERICA: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             643

TABLE 878            LATIN AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             643

TABLE 879            LATIN AMERICA: AUTOINJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             643

TABLE 880            LATIN AMERICA: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             644

TABLE 881            LATIN AMERICA: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             644

TABLE 882            LATIN AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           644

TABLE 883            LATIN AMERICA: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             645

TABLE 884            LATIN AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 645

TABLE 885            LATIN AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          646

TABLE 886            LATIN AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 646

TABLE 887            LATIN AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             647

TABLE 888            LATIN AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 647

TABLE 889            LATIN AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          647

TABLE 890            LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 648

TABLE 891            LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 648

TABLE 892            LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 649

TABLE 893            LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 649

TABLE 894            LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             650

TABLE 895            LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)                 650

TABLE 896            LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 651

TABLE 897            LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             651

TABLE 898            BRAZIL: KEY MACROECONOMIC INDICATORS                 652

TABLE 899            BRAZIL: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             652

TABLE 900            BRAZIL: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             653

TABLE 901            BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             653

TABLE 902            BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             653

TABLE 903            BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             654

TABLE 904            BRAZIL: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 654

TABLE 905            BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             654

TABLE 906            BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             655

TABLE 907            BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             655

TABLE 908            BRAZIL: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      655

TABLE 909            BRAZIL: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             656

TABLE 910            BRAZIL: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             656

TABLE 911            BRAZIL: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     656

TABLE 912          BRAZIL: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             657

TABLE 913            BRAZIL: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             657

TABLE 914            BRAZIL: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     657

TABLE 915            BRAZIL: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             658

TABLE 916            BRAZIL: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 658

TABLE 917            BRAZIL: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             659

TABLE 918            BRAZIL: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 659

TABLE 919            BRAZIL: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             659

TABLE 920            BRAZIL: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             660

TABLE 921            BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 660

TABLE 922            BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 661

TABLE 923            BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          661

TABLE 924            BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)        662

TABLE 925            BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 662

TABLE 926            BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             663

TABLE 927            BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 663

TABLE 928            BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             664

TABLE 929            MEXICO: KEY MACROECONOMIC INDICATORS                 664

TABLE 930            MEXICO: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             665

TABLE 931            MEXICO: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             665

TABLE 932            MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

2023–2030 (USD BILLION)             665

TABLE 933            MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             666

TABLE 934            MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

2023–2030 (USD BILLION)             666

TABLE 935            MEXICO: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)          666

TABLE 936            MEXICO: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             667

TABLE 937            MEXICO: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             667

TABLE 938            MEXICO: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             667

TABLE 939            MEXICO: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      668

TABLE 940            MEXICO: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             668

TABLE 941          MEXICO: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             668

TABLE 942            MEXICO: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     669

TABLE 943            MEXICO: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)      669

TABLE 944            MEXICO: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)             669

TABLE 945            MEXICO: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)     670

TABLE 946            MEXICO: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             670

TABLE 947            MEXICO: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 671

TABLE 948            MEXICO: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             671

TABLE 949            MEXICO: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)          672

TABLE 950            MEXICO: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE,

2023–2030 (USD BILLION)             672

TABLE 951            MEXICO: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 672

TABLE 952            MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)             673

TABLE 953            MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             673

TABLE 954            MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY TYPE, 2023–2030 (USD BILLION)          674

TABLE 955            MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS,

BY TYPE, 2023–2030 (USD BILLION)          674

TABLE 956            MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             675

TABLE 957            MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             675

TABLE 958            MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)             676

TABLE 959            MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             676

TABLE 960            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          677

TABLE 961            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          677

TABLE 962            REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,

BY MATERIAL, 2023–2030 (USD BILLION)               678

TABLE 963            REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,

BY PRODUCT, 2023–2030 (USD BILLION)                678

TABLE 964            REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,

BY USABILITY, 2023–2030 (USD BILLION)               678

TABLE 965            REST OF LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             679

TABLE 966            REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             679

TABLE 967            REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             680

TABLE 968            REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)                 680

TABLE 969            REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             681

TABLE 970            REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             681

TABLE 971            REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             681

TABLE 972            REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             682

TABLE 973            REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             682

TABLE 974            REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             682

TABLE 975            REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             683

TABLE 976            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)             683

TABLE 977            REST OF LATIN AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 684

TABLE 978            REST OF LATIN AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          684

TABLE 979            REST OF LATIN AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             685

TABLE 980            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)             685

TABLE 981            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)             685

TABLE 982            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 686

TABLE 983            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 686

TABLE 984            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)             687

TABLE 985            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)             687

TABLE 986            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)          688

TABLE 987            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET,

BY USAGE PATTERN, 2023–2030 (USD BILLION) 688

TABLE 988            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 689

TABLE 989            REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)                 689

TABLE 990            MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION)                 691

TABLE 991            MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          691

TABLE 992            MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 691

TABLE 993            MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET,

BY MATERIAL, 2023–2030 (USD BILLION)               692

TABLE 994            MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET,

BY PRODUCT, 2023–2030 (USD BILLION)                692

TABLE 995            MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET,

BY USABILITY, 2023–2030 (USD BILLION)               692

TABLE 996            MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             693

TABLE 997            MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             693

TABLE 998            MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             694

TABLE 999            MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             694

TABLE 1000         MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             695

TABLE 1001         MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             695

TABLE 1002         MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             695

TABLE 1003         MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             696

TABLE 1004         MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             696

TABLE 1005         MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             696

TABLE 1006         MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             697

TABLE 1007         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)             697

TABLE 1008         MIDDLE EAST & AFRICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 697

TABLE 1009         MIDDLE EAST & AFRICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          698

TABLE 1010         MIDDLE EAST & AFRICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             698

TABLE 1011         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)             698

TABLE 1012         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)             699

TABLE 1013         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 699

TABLE 1014         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 700

TABLE 1015         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)             700

TABLE 1016         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)             701

TABLE 1017         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)          701

TABLE 1018         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET,

BY USAGE PATTERN, 2023–2030 (USD BILLION) 702

TABLE 1019         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 702

TABLE 1020         MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)                 703

TABLE 1021         GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             704

TABLE 1022         GCC COUNTRIES: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 704

TABLE 1023         GCC COUNTRIES: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             704

TABLE 1024         GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)                 705

TABLE 1025         GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)                 705

TABLE 1026         GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)                 705

TABLE 1027         GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             706

TABLE 1028         GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             706

TABLE 1029         GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             707

TABLE 1030         GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             707

TABLE 1031         GCC COUNTRIES: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             708

TABLE 1032         GCC COUNTRIES: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             708

TABLE 1033         GCC COUNTRIES: AUTOINJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             708

TABLE 1034         GCC COUNTRIES: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             709

TABLE 1035         GCC COUNTRIES: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             709

TABLE 1036         GCC COUNTRIES: PEN INJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             709

TABLE 1037         GCC COUNTRIES: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             710

TABLE 1038         GCC COUNTRIES: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 710

TABLE 1039         GCC COUNTRIES: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          711

TABLE 1040         GCC COUNTRIES: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 711

TABLE 1041         GCC COUNTRIES: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             712

TABLE 1042         GCC COUNTRIES: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          712

TABLE 1043         GCC COUNTRIES: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          712

TABLE 1044         GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 713

TABLE 1045         GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 713

TABLE 1046         GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 714

TABLE 1047         GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 714

TABLE 1048         GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             715

TABLE 1049         GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)                 715

TABLE 1050         GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 716

TABLE 1051         GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             716

TABLE 1052         SAUDI ARABIA: KEY MACROECONOMIC INDICATORS      717

TABLE 1053         SAUDI ARABIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE,

2023–2030 (USD BILLION)           717

TABLE 1054         SAUDI ARABIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             718

TABLE 1055         SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)                 718

TABLE 1056         SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             718

TABLE 1057         SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)                 719

TABLE 1058         SAUDI ARABIA: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             719

TABLE 1059         SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             719

TABLE 1060         SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             720

TABLE 1061         SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             720

TABLE 1062         SAUDI ARABIA: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             721

TABLE 1063         SAUDI ARABIA: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             721

TABLE 1064         SAUDI ARABIA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           721

TABLE 1065         SAUDI ARABIA: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             722

TABLE 1066         SAUDI ARABIA: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             722

TABLE 1067         SAUDI ARABIA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)           722

TABLE 1068         SAUDI ARABIA: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             723

TABLE 1069         SAUDI ARABIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 723

TABLE 1070         SAUDI ARABIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          724

TABLE 1071         SAUDI ARABIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             724

TABLE 1072         SAUDI ARABIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             725

TABLE 1073         SAUDI ARABIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 725

TABLE 1074         SAUDI ARABIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)                 725

TABLE 1075         SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)             726

TABLE 1076         SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             726

TABLE 1077         SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 727

TABLE 1078         SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 727

TABLE 1079         SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)             728

TABLE 1080         SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2023–2030 (USD BILLION)             728

TABLE 1081         SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 729

TABLE 1082         SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             729

TABLE 1083         UNITED ARAB EMIRATES (UAE): KEY MACROECONOMIC INDICATORS              730

TABLE 1084         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)             730

TABLE 1085         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY DEVICES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          731

TABLE 1086         UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET,

BY MATERIAL, 2023–2030 (USD BILLION)               731

TABLE 1087         UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET,

BY PRODUCT, 2023–2030 (USD BILLION)                731

TABLE 1088         UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET,

BY USABILITY, 2023–2030 (USD BILLION)               732

TABLE 1089         UNITED ARAB EMIRATES (UAE): SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)             732

TABLE 1090         UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET,

BY PRODUCT, 2023–2030 (USD BILLION)                732

TABLE 1091         UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET,

BY TECHNOLOGY, 2023–2030 (USD BILLION)      733

TABLE 1092         UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)                 733

TABLE 1093         UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             734

TABLE 1094         UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             734

TABLE 1095         UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             734

TABLE 1096         UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             735

TABLE 1097         UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             735

TABLE 1098         UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             735

TABLE 1099         UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             736

TABLE 1100         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 736

TABLE 1101         UNITED ARAB EMIRATES (UAE): CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)          737

TABLE 1102         UNITED ARAB EMIRATES (UAE): NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)             737

TABLE 1103         UNITED ARAB EMIRATES (UAE): COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 738

TABLE 1104         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 738

TABLE 1105         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)        738

TABLE 1106         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 739

TABLE 1107         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 739

TABLE 1108         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 740

TABLE 1109         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 740

TABLE 1110         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)         741

TABLE 1111         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET,

BY USAGE PATTERN, 2023–2030 (USD BILLION) 741

TABLE 1112         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 742

TABLE 1113         UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET,

BY END USER, 2023–2030 (USD BILLION)                742

TABLE 1114         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY PRODUCTS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          743

TABLE 1115         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY DEVICES MARKET,

BY TYPE, 2023–2030 (USD BILLION)          743

TABLE 1116         REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET,

BY MATERIAL, 2023–2030 (USD BILLION)               744

TABLE 1117         REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET,

BY PRODUCT, 2023–2030 (USD BILLION)                744

TABLE 1118         REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET,

BY USABILITY, 2023–2030 (USD BILLION)               744

TABLE 1119         REST OF GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE,

2023–2030 (USD BILLION)             745

TABLE 1120         REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)                 745

TABLE 1121         REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             746

TABLE 1122         REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)                 746

TABLE 1123         REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             747

TABLE 1124         REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY TECHNOLOGY,

2023–2030 (USD BILLION)             747

TABLE 1125         REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             747

TABLE 1126         REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             748

TABLE 1127         REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             748

TABLE 1128         REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             748

TABLE 1129         REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             749

TABLE 1130         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)             749

TABLE 1131         REST OF GCC COUNTRIES: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 750

TABLE 1132         REST OF GCC COUNTRIES: NOVEL DRUG DELIVERY FORMULATIONS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          750

TABLE 1133         REST OF GCC COUNTRIES: COLLOIDAL DISPERSIONS MARKET, BY TYPE,

2023–2030 (USD BILLION)             751

TABLE 1134         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)             751

TABLE 1135         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)             751

TABLE 1136         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 752

TABLE 1137         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 752

TABLE 1138         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)             753

TABLE 1139         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)             753

TABLE 1140         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)          754

TABLE 1141         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET,

BY USAGE PATTERN, 2023–2030 (USD BILLION) 754

TABLE 1142         REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 755

TABLE 1143         NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2023–2030 (USD BILLION)             755

TABLE 1144         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)             756

TABLE 1145         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)             756

TABLE 1146         REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)             757

TABLE 1147         REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)             757

TABLE 1148         REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)             757

TABLE 1149         REST OF MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)             758

TABLE 1150         REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET,

BY PRODUCT, 2023–2030 (USD BILLION)                758

TABLE 1151         REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET,

BY TECHNOLOGY, 2023–2030 (USD BILLION)      759

TABLE 1152         REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET,

BY USABILITY, 2023–2030 (USD BILLION)               759

TABLE 1153         REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             760

TABLE 1154         REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)             760

TABLE 1155         REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             760

TABLE 1156         REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             761

TABLE 1157         REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY PRODUCT,

2023–2030 (USD BILLION)             761

TABLE 1158         REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY DESIGN,

2023–2030 (USD BILLION)             761

TABLE 1159         REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY USABILITY,

2023–2030 (USD BILLION)             762

TABLE 1160         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 762

TABLE 1161         REST OF MIDDLE EAST & AFRICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)          763

TABLE 1162         REST OF MIDDLE EAST & AFRICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)             763

TABLE 1163         REST OF MIDDLE EAST & AFRICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 764

TABLE 1164         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 764

TABLE 1165         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)        764

TABLE 1166         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET,

BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)                 765

TABLE 1167         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 765

TABLE 1168         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 766

TABLE 1169         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 766

TABLE 1170         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)         767

TABLE 1171         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET,

BY USAGE PATTERN, 2023–2030 (USD BILLION) 767

TABLE 1172         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET,

BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)                 768

TABLE 1173         REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET,

BY END USER, 2023–2030 (USD BILLION)                768

TABLE 1174         OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INJECTABLE DRUG DELIVERY MARKET        770

TABLE 1175         INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS:

DEGREE OF COMPETITION         774

TABLE 1176         INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS:

DEGREE OF COMPETITION         776

TABLE 1177         INJECTABLE DRUG DELIVERY DEVICES MARKET: REGION FOOTPRINT 783

TABLE 1178         INJECTABLE DRUG DELIVERY DEVICES MARKET: PRODUCT TYPE FOOTPRINT 783

TABLE 1179         INJECTABLE DRUG DELIVERY DEVICES MARKET: USAGE PATTERN FOOTPRINT                784

TABLE 1180         INJECTABLE DRUG DELIVERY DEVICES MARKET: THERAPEUTIC APPLICATION FOOTPRINT      785

TABLE 1181         INJECTABLE DRUG DELIVERY DEVICES MARKET: SITE OF ADMINISTRATION FOOTPRINT            786

TABLE 1182         INJECTABLE DRUG DELIVERY DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES         789

TABLE 1183         INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES              790

TABLE 1184         INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: REGION FOOTPRINT 794

TABLE 1185         INJECTABLE DRUG DELIVERY FORMULATIONS MARKET:

PRODUCT TYPE FOOTPRINT     795

TABLE 1186         INJECTABLE DRUG DELIVERY FORMULATIONS MARKET:

FORMULATION PACKAGING FOOTPRINT            796

TABLE 1187         INJECTABLE DRUG DELIVERY FORMULATIONS MARKET:

THERAPEUTIC APPLICATION FOOTPRINT          797

TABLE 1188         INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: SITE OF ADMINISTRATION TYPE FOOTPRINT                 798

TABLE 1189         INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: DETAILED LIST OF KEY STARTUPS/SMES         801

TABLE 1190         INJECTABLE DRUG DELIVERY FORMULATIONS MARKET:

COMPETITIVE BENCHMARKING OF STARTUPS/SMES    802

TABLE 1191         INJECTABLE DRUG DELIVERY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025        803

TABLE 1192         INJECTABLE DRUG DELIVERY MARKET: DEALS, JANUARY 2022–MARCH 2025         804

TABLE 1193         INJECTABLE DRUG DELIVERY MARKET: EXPANSIONS,

JANUARY 2022–MARCH 2025         805

TABLE 1194         CARDINAL HEALTH: COMPANY OVERVIEW                 806

TABLE 1195         CARDINAL HEALTH: PRODUCTS OFFERED                 807

TABLE 1196         CARDINAL HEALTH: EXPANSIONS, JANUARY 2022–MARCH 2025             808

TABLE 1197         BD: COMPANY OVERVIEW           810

TABLE 1198         BD: PRODUCTS OFFERED            811

TABLE 1199         BD: DEALS, JANUARY 2022–MARCH 2025 814

TABLE 1200         BD: EXPANSIONS, JANUARY 2022–MARCH 2025                 815

TABLE 1201         B. BRAUN SE: COMPANY OVERVIEW       816

TABLE 1202         B. BRAUN SE: PRODUCTS OFFERED        817

TABLE 1203         BAXTER: COMPANY OVERVIEW 820

TABLE 1204         BAXTER: PRODUCTS OFFERED 821

TABLE 1205         BAXTER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025              822

TABLE 1206         TERUMO CORPORATION: COMPANY OVERVIEW          824

TABLE 1207         TERUMO CORPORATION: PRODUCTS OFFERED                 825

TABLE 1208         TERUMO CORPORATION: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         826

TABLE 1209         TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2025         827

TABLE 1210         PHILLIPS-MEDSIZE CORPORATION (MOLEX): COMPANY OVERVIEW   828

TABLE 1211         PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCTS OFFERED    828

TABLE 1212         PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025        829

TABLE 1213         PHILLIPS-MEDSIZE CORPORATION (MOLEX): DEALS, JANUARY 2022–MARCH 2025         829

TABLE 1214         PHILLIPS-MEDSIZE CORPORATION (MOLEX): EXPANSIONS,

JANUARY 2022–MARCH 2025         829

TABLE 1215         NIPRO: COMPANY OVERVIEW   830

TABLE 1216         NIPRO: PRODUCTS OFFERED    831

TABLE 1217         NIPRO: EXPANSIONS, JANUARY 2022–MARCH 2025        832

TABLE 1218         ICU MEDICAL, INC.: COMPANY OVERVIEW                 833

TABLE 1219         ICU MEDICAL, INC.: PRODUCTS OFFERED                 834

TABLE 1220         ICU MEDICAL, INC.: DEALS, JANUARY 2022–MARCH 2025       835

TABLE 1221         WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW   836

TABLE 1222         WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED    837

TABLE 1223         WEST PHARMACEUTICAL SERVICES, INC.: DEALS, JANUARY 2022–MARCH 2025         838

TABLE 1224         WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS,

JANUARY 2022–MARCH 2025         838

TABLE 1225         GERRESHEIMER AG: COMPANY OVERVIEW                 840

TABLE 1226         GERRESHEIMER AG: PRODUCTS OFFERED                 841

TABLE 1227         GERRESHEIMER AG: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         843

TABLE 1228         GERRESHMEIMER AG: DEALS, JANUARY 2022–MARCH 2025       843

TABLE 1229         GERRESHMEIMER AG: EXPANSIONS, JANUARY 2022–MARCH 2025             844

TABLE 1230         STEVANATO: COMPANY OVERVIEW       845

TABLE 1231         STEVANATO: PRODUCTS OFFERED        846

TABLE 1232         STEVANATO: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         847

TABLE 1233         STEVANATO: DEALS, JANUARY 2022–MARCH 2025        847

TABLE 1234         STEVANATO: EXPANSIONS, JANUARY 2022–MARCH 2025       848

TABLE 1235         SCHOTT PHARMA: COMPANY OVERVIEW                 849

TABLE 1236         SCHOTT PHARMA: PRODUCTS OFFERED                 850

TABLE 1237         SCHOTT PHARMA: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         851

TABLE 1238         SCHOTT PHARMA: DEALS, JANUARY 2022–MARCH 2025       851

TABLE 1239         SCOTT PHARMA: EXPANSIONS, JANUARY 2022–MARCH 2025       852

TABLE 1240         MEDMIX: COMPANY OVERVIEW                853

TABLE 1241         MEDMIX: PRODUCTS OFFERED 854

TABLE 1242         MEDMIX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025              855

TABLE 1243         MEDMIX: DEALS, JANUARY 2022–APRIL 2025                 855

TABLE 1244         SOLM: COMPANY OVERVIEW     856

TABLE 1245         SOLM: PRODUCTS OFFERED      856

TABLE 1246         YPSOMED: COMPANY OVERVIEW             858

TABLE 1247         YPSOMED: PRODUCTS OFFERED              859

TABLE 1248         YPSOMED: DEALS, JANUARY 2022–MARCH 2025                 860

TABLE 1249         YPSOMED: EXPANSIONS, JANUARY 2022–MARCH 2025        861

TABLE 1250         OWEN MUMFORD: COMPANY OVERVIEW                 862

TABLE 1251         HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.: COMPANY OVERVIEW       863

TABLE 1252         POLYMEDICURE: COMPANY OVERVIEW                 864

TABLE 1253         UNION MEDICO INC.: COMPANY OVERVIEW                 865

TABLE 1254         SHL MEDICAL: COMPANY OVERVIEW    866

TABLE 1255         ELCAM MEDICAL: COMPANY OVERVIEW                 867

TABLE 1256         JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW   868

TABLE 1257         JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED    869

TABLE 1258         JOHNSON & JOHNSON SERVICES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025        871

TABLE 1259         JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022–APRIL 2025            873

TABLE 1260         F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW          874

TABLE 1261         F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED             875

TABLE 1262         F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–APRIL 2025            877

TABLE 1263         PFIZER INC.: COMPANY OVERVIEW         880

TABLE 1264         PFIZER INC.: PRODUCTS OFFERED          881

TABLE 1265         PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 887

TABLE 1266         PFIZER INC.: DEALS, JANUARY 2022–APRIL 2025                 888

TABLE 1267         MERCK & CO., INC.: COMPANY OVERVIEW                 890

TABLE 1268         MERCK & CO., INC.: PRODUCTS OFFERED                 891

TABLE 1269         MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–APRIL 2025            893

TABLE 1270         MERCK & CO., INC.: DEALS, JANUARY 2022–APRIL 2025           895

TABLE 1271         MERCK & CO., INC.: EXPANSIONS, JANUARY 2022–APRIL 2025                896

TABLE 1272         NOVARTIS AG: COMPANY OVERVIEW    898

TABLE 1273         NOVARTIS AG: PRODUCTS OFFERED     899

TABLE 1274         NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–APRIL 2025            900

TABLE 1275         NOVARTIS AG: DEALS, JANUARY 2022–APRIL 2025        901

TABLE 1276         NOVARTIS AG: EXPANSIONS, JANUARY 2022–APRIL 2025           902

TABLE 1277         BAYER AG: COMPANY OVERVIEW             903

TABLE 1278         BAYER AG: PRODUCTS OFFERED              904

TABLE 1279         BAYER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 905

TABLE 1280         BAYER AG: EXPANSIONS, JANUARY 2022–APRIL 2025        906

TABLE 1281         ASTRAZENECA: COMPANY OVERVIEW  907

TABLE 1282         ASTRAZENECA: PRODUCTS OFFERED   908

TABLE 1283         ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–APRIL 2025            909

TABLE 1284         ASTRAZENECA: DEALS, JANUARY 2022–APRIL 2025        914

TABLE 1285         ASTRAZENECA: EXPANSIONS, JANUARY 2022–APRIL 2025           915

TABLE 1286         TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW               916

TABLE 1287         TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED                917

TABLE 1288         TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025                919

TABLE 1289         TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS,

JANUARY 2022–APRIL 2025            921

TABLE 1290         TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS,

JANUARY 2022–APRIL 2025            922

TABLE 1291         ELI LILLY AND COMPANY: COMPANY OVERVIEW          923

TABLE 1292         ELI LILLY AND COMPANY: PRODUCTS OFFERED                 924

TABLE 1293         ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–APRIL 2025            925

TABLE 1294         ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–APRIL 2025            926

TABLE 1295         AMGEN INC.: COMPANY OVERVIEW        929

TABLE 1296         AMGEN INC.: PRODUCTS OFFERED         930

TABLE 1297         AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 931

TABLE 1298         AMGEN INC.: DEALS, JANUARY 2022–APRIL 2025                 932

TABLE 1299         AMGEN INC.: EXPANSIONS, JANUARY 2022–APRIL 2025           932

TABLE 1300         NOVO NORDISK A/S: COMPANY OVERVIEW                 934

TABLE 1301         NOVO NORDISK A/S: PRODUCTS OFFERED                 935

TABLE 1302         NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–APRIL 2025            936

TABLE 1303         NOVO NORDISK A/S: DEALS, JANUARY 2022–APRIL 2025           937

TABLE 1304         NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–APRIL 2025                937

TABLE 1305         REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW   939

TABLE 1306         REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED    940

TABLE 1307         REGENERON PHARMACEUTICALS INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025        940

TABLE 1308         REGENERON PHARMACEUTICALS INC.: DEALS, JANUARY 2022–APRIL 2025            942

TABLE 1309         FRESENIUS KABI AG: COMPANY OVERVIEW                 943

TABLE 1310         FRESENIUS KABI AG: PRODUCTS OFFERED                 944

TABLE 1311         FRESENIUS KABI AG: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–APRIL 2025            945

TABLE 1312         UCB S.A.: COMPANY OVERVIEW                946

TABLE 1313         UCB S.A.: PRODUCTS OFFERED 947

TABLE 1314         UCB S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 948

TABLE 1315         BIO-THERA SOLUTIONS, LTD.: COMPANY OVERVIEW          949

TABLE 1316         BIO-THERA SOLUTIONS, LTD.: PRODUCTS OFFERED             950

TABLE 1317         BIO-THERA SOLUTIONS, LTD.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–APRIL 2025            950

TABLE 1318         SAGENT: COMPANY OVERVIEW                951

TABLE 1319         VALNEVA SE: COMPANY OVERVIEW       954

TABLE 1320         XERIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW          955

TABLE 1321         PHARMAESSENTIA CORPORATION: COMPANY OVERVIEW          956

TABLE 1322         HERON THERAPEUTICS, INC.: COMPANY OVERVIEW          957

LIST OF FIGURES

FIGURE 1              INJECTABLE DRUG DELIVERY MARKET SEGMENTATION              73

FIGURE 2              INJECTABLE DRUG DELIVERY MARKET REGIONAL SEGMENTATION       74

FIGURE 3              INJECTABLE DRUG DELIVERY MARKET: RESEARCH DESIGN         78

FIGURE 4              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND

DEMAND-SIDE PARTICIPANTS  83

FIGURE 5              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,

DESIGNATION, AND REGION     83

FIGURE 6              BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE):

BY END USER, DESIGNATION, AND REGION        84

FIGURE 7              MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS            85

FIGURE 8              INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 86

FIGURE 9              TOP-DOWN APPROACH                87

FIGURE 10            BOTTOM-UP APPROACH              87

FIGURE 11            DATA TRIANGULATION METHODOLOGY                 90

FIGURE 12            INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT,

2025 VS. 2030 (USD BILLION)       93

FIGURE 13            INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION,

2025 VS. 2030 (USD BILLION)       94

FIGURE 14            INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION,

2025 VS. 2030 (USD BILLION)       94

FIGURE 15            INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN,

2025 VS. 2030 (USD BILLION)       95

FIGURE 16            INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION,

2025 VS. 2030 (USD MILLION)      96

FIGURE 17            INJECTABLE DRUG DELIVERY MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      96

FIGURE 18            INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT            97

FIGURE 19            RISING CHRONIC DISEASES TO DRIVE MARKET                 99

FIGURE 20            DEVICES SEGMENT AND US DOMINATED NORTH AMERICAN

INJECTABLE DRUG DELIVERY MARKET IN 2024  100

FIGURE 21            ASIA PACIFIC TO DOMINATE MARKET DURING FORECAST PERIOD         100

FIGURE 22            CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD         101

FIGURE 23            DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD  101

FIGURE 24            INJECTABLE DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                 102

FIGURE 25            TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS   111

FIGURE 26            AVERAGE SELLING PRICE TREND OF KEY PLAYERS,

BY PEN INJECTORS (INSULIN PENS), 2024 (USD)                113

FIGURE 27            INJECTABLE DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS              115

FIGURE 28            INJECTABLE DRUG DELIVERY MARKET: SUPPLY CHAIN ANALYSIS              117

FIGURE 29            INJECTABLE DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS  118

FIGURE 30            INJECTABLE DRUG DELIVERY MARKET: INVESTMENT AND FUNDING

SCENARIO, 2021–2023      120

FIGURE 31            INJECTABLE DRUG DELIVERY MARKET: PATENT ANALYSIS,

JANUARY 2014–MARCH 2025         124

FIGURE 32            TOP APPLICANTS FOR INJECTABLE DRUG DELIVERY PATENTS,

JANUARY 2014–MARCH 2025         125

FIGURE 33            INJECTABLE DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS           136

FIGURE 34            KEY STAKEHOLDERS IN BUYING PROCESS FOR HOSPITALS &

CLINICS (INJECTABLE DRUG DELIVERY DEVICES)           138

FIGURE 35            BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY DEVICES FOR

TOP THREE END USERS                139

FIGURE 36            KEY BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY

WITH FORMULATIONS FOR TOP THREE END USERS      139

FIGURE 37            TOTAL NUMBER OF TRIALS COMPLETED/YEAR, 2024–2032              148

FIGURE 38            AI USE CASES     151

FIGURE 39            INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT, 2024 375

FIGURE 40            NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT 377

FIGURE 41            ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT       522

FIGURE 42            REVENUE ANALYSIS OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2022−2024              772

FIGURE 43            REVENUE ANALYSIS OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2022−2024                 772

FIGURE 44            MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2024            773

FIGURE 45            RANKING OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2024                775

FIGURE 46            MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2024                 776

FIGURE 47            RANKING OF KEY INJECTABLE DRUG DELIVERY FORMULATION

MANUFACTURERS, 2024                 777

FIGURE 48            INJECTABLE DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARISON             778

FIGURE 49            R&D EXPENDITURE OF KEY PLAYERS IN INJECTABLE DRUG

DELIVERY MARKET, 2022−2024  778

FIGURE 50            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                779

FIGURE 51            YEAR-TO-YEAR (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                779

FIGURE 52            INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY

EVALUATION MATRIX (KEY PLAYERS), 2024         781

FIGURE 53            INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT             782

FIGURE 54            INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY

EVALUATION MATRIX (STARTUPS/SMES), 2024 788

FIGURE 55            INJECTABLE DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX, 2024  792

FIGURE 56            INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT             793

FIGURE 57            INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY

EVALUATION MATRIX (STARTUPS/SMES), 2023 800

FIGURE 58            CARDINAL HEALTH: COMPANY SNAPSHOT (2024)    807

FIGURE 59            BD: COMPANY SNAPSHOT (2024)              811

FIGURE 60            B. BRAUN SE: COMPANY SNAPSHOT (2023)                 817

FIGURE 61            BAXTER: COMPANY SNAPSHOT (2024)   821

FIGURE 62            TERUMO CORPORATION: COMPANY SNAPSHOT (2023)             825

FIGURE 63            NIPRO: COMPANY SNAPSHOT (2024)       831

FIGURE 64            ICU MEDICAL, INC.: COMPANY SNAPSHOT (2024)    834

FIGURE 65            WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2024)      837

FIGURE 66            GERRESHEIMER AG: COMPANY SNAPSHOT (2024)    841

FIGURE 67            STEVANATO: COMPANY SNAPSHOT (2024)                 846

FIGURE 68            SCHOTT PHARMA: COMPANY SNAPSHOT (2024)                 850

FIGURE 69            MEDMIX: COMPANY SNAPSHOT (2024)  854

FIGURE 70            YPSOMED: COMPANY SNAPSHOT (2024)                 859

FIGURE 71            JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)      869

FIGURE 72            F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)             875

FIGURE 73            PFIZER INC.: COMPANY SNAPSHOT (2024)                 881

FIGURE 74            MERCK & CO., INC.: COMPANY SNAPSHOT (2024)    891

FIGURE 75            NOVARTIS AG: COMPANY SNAPSHOT (2024)                 899

FIGURE 76            BAYER AG: COMPANY SNAPSHOT (2024)                 904

FIGURE 77            ASTRAZENECA: COMPANY SNAPSHOT (2024)                 908

FIGURE 78            TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2024)  917

FIGURE 79            ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024)             924

FIGURE 80            AMGEN INC.: COMPANY SNAPSHOT (2024)                 929

FIGURE 81            NOVO NORDISK A/S: COMPANY SNAPSHOT (2024)    935

FIGURE 82            REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)      939

FIGURE 83            FRESENIUS KABI AG: COMPANY SNAPSHOT (2024)    943

FIGURE 84            UCB S.A.: COMPANY SNAPSHOT (2024)   947

FIGURE 85            BIO-THERA SOLUTIONS, LTD.: COMPANY SNAPSHOT (2024)             949

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧